Search

Your search keyword '"Keta D"' showing total 35 results
Start Over Author "Keta D"
35 results on '"Keta D"'

1. Management of a Difficult Airway Scenario in a Case of Hurler’s Syndrome with a D-Blade Video Laryngoscope

Author

Keta D. Thakkar, Ajay P. Hrishi, Manikandan Sethuraman, and Smita Vimala

Subjects
hurler’s syndrome, pediatric difficult airway, d-blade c-mac, Anesthesiology, RD78.3-87.3
Abstract

Hurler’s syndrome is a rare genetic disease characterized by progressive multiorgan accumulation of glycosaminoglycans. It is associated with progressive craniofacial, skeletal, and cardiac involvement, which increases the risk of anesthesia. Patients with Hurler’s syndrome could present as the worst airway management problem an anesthesiologist could deal with due to abnormal upper airway anatomy and limited neck manipulation, owing to the atlantoaxial instability. We report a case of difficult airway scenario of a child with Hurler’s syndrome, leading to an apparent cannot ventilate cannot intubate scenario, which was managed successfully with the help of a C-MAC video laryngoscope with unique D-blade. In Hurler’s syndrome, C-MAC with D-blade is an excellent tool in establishing an airway in a pediatric difficult airway scenario. Moreover, D-blade C-MAC could be considered as the primary tool for establishing an airway in pediatric patients with Hurler’s syndrome.

Published
2020
Full Text
View/download PDF

3. Effect of Different Surgical Positions on the Changes in Cerebral Venous Drainage in Patients Undergoing Neurosurgery: A Prospective Observational Study

Author

Keta D, Thakkar, Manikandan, Sethuraman, Ranganatha, Praveen C S, Smita, Vimala, Ajay Prasad, Hrishi P, and Unnikrishnan, Prathapadas

Subjects
Anesthesiology and Pain Medicine, Surgery, Neurology (clinical)
Abstract

Some patient positions employed to facilitate neurosurgery can compromise cerebral venous drainage and lead to increased intracranial pressure, intraoperative bleeding, and brain bulge. This study evaluated the impact of different surgical positions on internal jugular vein (IJV) flow as a measure of cerebral venous drainage and on optic nerve sheath diameter (ONSD) as an indirect assessment of intracranial pressure.Ninety patients scheduled for elective primary brain tumor resection surgery were included in 3 groups of 30 each according to the surgical position: supine, prone, or lateral. Bilateral IJV flow was recorded at 3-time points: before the induction of anesthesia in the supine position (T0), 10 minutes after the induction of anesthesia in the supine position (T1), and 10 minutes after final positioning (T2). The ONSD was measured at T1 and T2.Mean IJV flow decreased from baseline by 36%, 10% and 38% in the supine, prone and lateral position groups, respectively. Mean IJV flow was 1005.9±463 mL/min versus 634.7±245 mL/min (P=0.036) in Group S, 752.5±384.8 mL/min versus 672.3±391.0 mL/min (P=0.002) in group P, and 831.8±337.4 mL/min versus 514.4±305.3 mL/min (P0.001) in group L at T0 and T2, respectively. Mean ONSD did not change between T1 and T2 in Groups S and P but increased in group L (P0.05).Mean IJV flow decreased from baseline following the final neurosurgical positioning. Ultrasound-guided assessment of IJV flow could be a useful tool to quantify position-related changes in IJV drainage.

Published
2022

5. Evidence for an association between KIBRA and late-onset Alzheimer's disease

Author

Corneveaux, Jason J., Liang, Winnie S., Reiman, Eric M., Webster, Jennifer A., Myers, Amanda J., Zismann, Victoria L., Joshipura, Keta D., Pearson, John V., Hu-Lince, Diane, Craig, David W., Coon, Keith D., Dunckley, Travis, Bandy, Daniel, Lee, Wendy, Chen, Kewei, Beach, Thomas G., Mastroeni, Diego, Grover, Andrew, Ravid, Rivka, Sando, Sigrid B., Aasly, Jan O., Heun, Reinhard, Jessen, Frank, Kölsch, Heike, Rogers, Joseph, Hutton, Michael L., Melquist, Stacey, Petersen, Ron C., Alexander, Gene E., Caselli, Richard J., Papassotiropoulos, Andreas, Stephan, Dietrich A., and Huentelman, Matthew J.

Published
2010
Full Text
View/download PDF

6. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction

Author

Schulz, Stefanie, Richardt, Gert, Laugwitz, Karl-Ludwig, Morath, Tanja, Neudecker, Julia, Hoppmann, Petra, Mehran, Roxana, Gershlick, Anthony H., Tölg, Ralph, Anette Fiedler, K., Abdel-Wahab, Mohamed, Kufner, Sebastian, Schneider, Simon, Schunkert, Heribert, Ibrahim, Tareq, Mehilli, Julinda, Kastrati, Adnan, Kastrati, A., Mehilli, J., Richardt, G., Mehran, R., Gershlick, A., Mehilli, J., Burgdorf, C., Byrne, R.A., Cassese, S., Fusaro, M., Hausleiter, J., Hengstenberg, C., Joner, M., Kasel, M., Kastrati, A., Massberg, S., Ott, I., Pache, J., Schunkert, H., Seyfarth, M., Sibbing, D., Tiroch, K., Laugwitz, K.-L., Ibrahim, T., Hoppmann, P., Schneider, S., Bradaric, C., Richardt, G., Abdel-Wahab, M., Geist, V., Schwarz, B., Sulimov, D., Tölg, R., Schulz, S., Schömig, G., von Merzljak, B., Luckmann, J., Ruf, J., Morath, T., Holle, H., Paul, H., Vogel, J., Hoesl, K., Rifatov, N., Pastor, I., Maimer-Rodrigues, F., Schulz, M., Neudecker, J., Mayer, K., Hofmann, F., Mann, J., Hauschke, D., Schmitt, C., Poci, D., Barthel, P., Ndrepepa, G., Keta, D., Byrne, R.A., Kufner, S., Piniek, S., Hurt, S., Kastrati, S., and Anette Fiedler, K.

Published
2014
Full Text
View/download PDF

8. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey

Author

Valgimigli, M, Costa, F, Byrne, R, Haude, M, Baumbach, A, Windecker, S, Aaroe, J, Aasa, M, Abdel-Salam, Am, Alaarag, Af, Accardi, R, Adel, A, Alcazar De La Torre, E, Alejos, R, Alfonso Jimenez, V, Alhashimi, Hmm, Aljeboury, A, Almeida De Sousa, J, Almusawi, A, Alshaikha, M, Altaf, S, Altahmody, Kea, Alvarez Contreras, Lr, Amarasena, N, Amoroso, G, Anderson, R, Ando, G, Andrade, J, Andreou, Ay, Angulo, J, Antonio, T, Aprigliano, G, Aquilina, M, Arafa, Seo, Aramberry, L, Arampatzis, Ca, Araujo, Jj, Asher, E, Ates, I, Athanasias, D, Auer, J, Auffret, V, Ayala, Fj, Baba, C, Baglioni, P, Bagur, R, Balam-Ortiz, E, Balducelli, M, Bam Pas, G, Barbash, Im, Barbosa, Ahp, Barbosa, R, Barnay, P, Barroso, L, Basti, A, Bax, M, Bayet, G, Beijk, Ma, Beltran, R, Berenguer Jofresa, A, Berroth, R, Berti, S, Berumen Dominguez, Le, Bhasin, A, Bhaya, M, Bianco, M, Biasco, L, Bikicki, M, Bonarjee, Vvs, Bonechi, F, Borges Santos, M, Boshev, M, Bouferrouk, A, Bounartzidi, M, Bousoula, E, Brie, D, Brtko, M, Brugaletta, S, Brull, Dj, Buchter, B, Buendia, R, Burzotta, F, Butz, T, Buzzetti, F, Bychowiec, B, Cadeddu, M, Campanile, A, Carneiro, Jg, Carrilho-Ferreira, P, Carrillo Guevara, Je, Carter, Aj, Casal-Heredia, H, Castiglioni, B, Castro Fabiano, L, Cavalcante Silva, R, Cavalcanti De Oliveira, D, Cavalcanti, Rc, Cavazza, C, Centemero, Mp, Chabane, Hk, Chamie, D, Chatzis, D, Chaves, Aj, Cheng, S, Chinchilla, H, Ciabatti, N, Cirillo, P, Citaku, H, Claeys, Mj, Clifford, C, Coceani, M, Coggiola, J, Cohen, Dj, Conway, Dsg, Cornelis, K, Coroleu, Sf, Corral, Jm, Cortese, B, Coskun, U, Costa, Ra, Coste, P, Coufal, Z, Cox, S, Cozma, A, Crean, P, Crenshaw, Mh, Cristian, U, Cruz-Alvarado, Je, Cuculi, F, Cuenza, L, Cyrne Carvalho, H, D'Ascenzo, F, D'Urbano, M, Damonte, A, Dan Florin, F, Dana, A, Dangoisse, V, De Backer, O, De Cock, D, De Vita, M, Debski, A, Delgado, A, Devadathan, S, Dhamrait, S, Di Lorenzo, E, Di Serafino, D, Diego-Nieto, A, Dievart, F, Diez, Jl, Dimitriadis, K, Dina, C, Doerner, O, Donahue, M, Donis, J, Drieghe, B, Drissi, Mf, Du Fretay, H, Dziewierz, A, Echavarria-Pinto, M, Echeverria Romero, Rg, Economou, F, Eftychiou, C, Egdell, R, El Hosieny, A, El Meguid, K, Elabbassi, W, Elesgerli, S, Elghetany, H, Elizondo, Jc, Elkahlout, A, Elrowiny, R, Elserafy, As, Emam, A, Emara, A, Emmanouil, P, Ercilla, J, Erglis, A, Eslam Taha, E, Esmaeil, S, Esposito, G, Ettori, F, Eugenio, N, Everaert, B, Ezquerra Aguilar, W, Falu, R, Farag, E, Farjalla, J, Feldman, L, Feldman, M, Felice, H, Fernandez-Nofrerias, E, Fernandez-Rodriguez, D, Ferranti, F, Ferreira, Q, Ferrone, M, Fleischmann, C, Flessas, D, Formigli, D, Fozilov, H, Fraccaro, C, Freitas, Jo, Fresco, C, Fridrich, V, Furmaniuk, J, Gagnor, A, Galasso, G, Galeazzi, Gl, Galli, S, Galvez Villacorta, V, Gandolfo, C, Garcia, E, Garcia-Blas, S, Garducci, S, Garg, S, Garro, N, Gatto, L, Georgiou, Mg, Ghanem, I, Ghose, T, Giacchi, G, Giang, Pt, Giesler, T, Giovino, M, Girardi, P, Girasis, C, Giunio, L, Giustino, G, Glatthor, C, Glogar, Hd, Golledge, P, Gomez Moreno, J, Gomez Recio, M, Gommeaux, A, Grantalis, G, Greco, F, Grundeken, Mj, Grunert, S, Gudmundsdottir, I, Guenoun, M, Guerios, E, Gupta, R, Gupta, S, Gutierrez, C, Hafeez, I, Halvorsen, S, Hamed Hussein, Ga, Hammoudeh, A, Hansen, Pr, Harb, S, Hawas, Jm, Hayrapetyan, H, Heintzen, Mp, Hengstenberg, C, Herity, N, Hernandez, F, Heyse, A, Hicham, D, Hildick-Smith, D, Hill, J, Hillani, A, Hiltrop, N, Hiramori, A, Hobson, Ar, Homan, Dj, Hooda, A, Ielasi, A, Ierna, S, Iftikhar, Ak, Ilic, I, Imai, Y, Imperadore, F, Indolfi, C, Iorga, V, Ipek, E, Ito, S, Jacksch, R, Jae-Sik, J, James, S, Jamshidi, P, Jerbi, J, Jimenez Quevedo, P, Jimenez-Navarro, M, Jimenez-Santos, M, Jin, Qh, Joksas, V, Jovic, D, Junejo, S, Kallel, R, Kamal, A, Kamiya, H, Kannan, D, Kantaria, M, Kapetanopoulos, A, Kara Ali, B, Karjalainen, Pp, Karthikeyan, Vj, Kato, R, Katsikis, A, Kefer, J, Keta, D, Ketteler, T, Khan, M, Kharlamov, A, Kinani, A, Kinani, T, Kinnaird, T, Kislo, A, Kiviniemi, T, Kleiban, A, Kluck, B, Kocayigit, I, Kokis, A, Komiyama, N, Konstantinos, L, Kordalis, A, Kozak, M, Krecki, R, Kristensen, Sd, Krizanic, F, Krsticevic, L, Kuex, H, Kukreja, N, Kulic, M, Kulikovskikh, Yv, Kulkarni, P, Kumar, N, Kumar Soni, A, Kuzmenko, E, L'Allier, Pl, Langner, O, Lapin, O, Lauer, B, Leclercq, F, Leibundgut, G, Leon Aliz, E, Leon, C, Leon, K, Leoncini, M, Leone, Am, Leroux, L, Lesiak, M, Letilovic, T, Lev, E, Linares Vicente, Ja, Lindsay, S, Loh, Ph, Loncar, G, Loo, B, Lopez, Mb, Lopez-Cuellar, J, Lozano, I, Luigia, P, Lunde, K, Lyczywek, M, Macdougall, D, Mafrici, A, Magni, V, Magro, M, Mainar, V, Makarovic, Z, Malik, N, Maly, M, Mansour, S, Marenco, Re, Maresta, A, Marinho, Ge, Marino, Rl, Marinucci, L, Martins, Hc, Martins, J, Mashayekhi, K, Masood, A, Maurer, E, Mavrogianni, Ad, Mazurek, T, Medina, A, Mehilli, J, Mellwig, Kp, Mendez, M, Mendiz, Oa, Meneses, A, Mercado, La, Mereuta, A, Mezzapelle, G, Milanovic, N, Mohamed, Sm, Mohanad, A, Mohanty, A, Moorthy, N, Morales, Fj, More, R, Moreno Samos, Jc, Moreno-Martinez, Fl, Moscato, F, Mossmann, M, Mrevlje, B, Muller-Eichelberg, A, Musumeci, G, Nadir Khan, M, Najim, S, Nakamura, S, Nakao, F, Naveri, H, Negus, B, Nerla, R, Nguyen, Ht, Niess, Gs, Nikas, Dn, Niroomand, F, Niva, J, Nogueira, Jw, Nombela-Franco, L, Notrica, M, Nouri, B, Nugue, O, Nunes, Gl, Ober, M, Ochoa, J, J. H., O, Ojeda, S, Oktay Tureli, H, Olowe, Y, Oluseun, A, Opolski, G, Ornelas, Ce, Otasevic, P, Ozturk, A, Padilla, F, Pagny, Jy, Paolantonio, D, Papaioannou, Gi, Parodi, G, Patil, Sn, Pavei, A, Pavia, A, Pavlidis, A, Pell, A, Percoco, Gf, Pernasetti, Lv, Pescoller, F, Petropoulakis, P, Piatti, L, Picardi, E, Pieroni, Dm, Pina, J, Pinheiro, Lf, Pinto, Fj, Pipa, Jl, Piroth, Z, Pisano, F, Podbregar, M, Polak, G, Polimeni, A, Postadzhiyan, A, Postu, M, Poulimenos, Le, Pow Chon Long, F, Poyet, R, Pradhan, A, Predescu, Lm, Prida, Xe, Saad, A, Prog, R, Pulikal, Dga, Qiangzhong, Pi, Radu, Md, Rajendran, D, Ram Anil Raj, Mr, Ramazzotti, V, Rapacciuolo, A, Ratib, K, Raungaard, B, Raviola, E, Reppas, E, Reyes, Ja, Rezek, M, Riess, Gj, Rifaie, O, Rigattieri, S, Rissanen, T, Ristic, Ad, Rittger, H, Roberts, J, Rodriguez Saavedra, A, Roik, M, Roshan Rao, K, Routledge, H, Rubboli, A, Rudolph, T, Rudzitis, A, Ruiters, A, Ruiz Ros, Ja, Ruiz-Garcia, J, Ruiz-Nodar, Jm, Sabate, M, Sabnis, G, Sabouret, P, Sacra, C, Saghatelyan, M, Sahin, M, Said, S, Salachas, Aj, Salas Llamas, Jp, Salih, A, Sanchez, Od, Sanchez-Gila, J, Sanchez-Perez, I, Santarelli, A, Sardovski, Sarenac, D, Sarma, J, Sarno, G, Savonitto, S, Sayied Abdullah, A, Schafer, A, Scherillo, M, Schneider, H, Schuhlen, H, Sciahbasi, A, Seca, L, Sedlon, P, Semenka, J, Serra, La, Sesana, M, Sethi, A, Sgueglia, Ga, Shaheen, S, Shahri, H, Sheiban, I, Shyu, Kg, Silva, Cef, Sionis, D, Siqueira, Da, Siqueira, Mj, Smits, P, Sobhy, M, Sokolov, M, Soliman, S, Somani, An, Sridhar, G, Stakos, D, Stasek, J, Stefanini, G, Steigen, Tk, Stewart, Stipal, R, Stochino, Ml, Stoel, Mg, Subla, Rm, Suliman, A, Summaria, F, Stoyanov, N, Syed, Aa, Tanaka, Y, Tashani, A, Tauzin, S, Tawade, N, Tawfik, M, Tayeh, O, Terzic, I, Testa, L, Thevan, B, Thiam, M, Tiecco, F, Tierala, I, Tilea, I, Tilsted, Hh, Tomasik, Ar, Tonev, I, Torres Bosco, A, Tousek, P, Townend, J, Tran Ngoc, T, Triantafyllou, K, Tsigkas, G, Tsioufis, C, Turri, M, Tyligadis, G, Ugo, F, Ultramari, Ft, Urban, P, Uren, N, Uretsky, Bf, Uribe, Ce, Usman, B, Valadez Molina, F, Van Houwelingen, Kg, Vandormael, M, Varvarovsky, I, Vassilis, V, Velasquez, D, Verdoia, M, Vermeersch, P, Vidal-Perez, R, Vinesh, J, Violini, R, Vista, Jh, Vogt, F, Vogt, M, Vokac, D, Vom Dahl, J, Vranckx, P, Wahab, A, Wang, R, Wang, Td, Wani, S, Weisz, Sh, Werner, Gs, Wilkinson, Jr, Wolf, A, Youssef, A, Yumoto, K, Zaderenko, N, Zaghloul Darwish, Am, Zahn, R, Zaro, T, Zavalloni, D, Zbinden, R, Zekanovic, D, Zhang, B, Zhang, C, Zhang, Yj, Zhonghan, N, Zingarelli, A, Zueco, J, Zuhairy, H, Abbate, A, Abdel Hamid, M, Abdelmegid, Maf, Acuna-Valerio, J, Adriaenssens, T, Agostoni, P, Aikot, H, Alameda, M, Alcaraz, H, Almendro-Delia, M, Altug Cakmak, H, Amir, A, Arjomand, A, Assomull, R, Atalar, E, Avramides, D, Aytek Simsek, M, Aznaouridis, K, Azpeitia, Y, Barnabas, C, Barsness, Gw, Bartorelli, Al, Basoglu, A, Benezet, J, Benincasa, S, Berland, J, Berrocal, Dh, Bett, N, Boskovic, S, Brandao, V, Caporale, R, Caprotta, F, Carrabba, N, Cazaux, P, Cheniti, G, Chinchilla Calix, H, Chung, Wy, Cicco, Na, Cieza, T, Clapp, B, Commeau, P, Cuellar, C, De Benedictis, M, De La Torre Hernandez, Jm, De Vroey, F, Degertekin, M, Eberli, Fr, Eggebrecht, H, Ekicibasi, E, Elmaraghi, M, Elod, P, Ergene, Ao, Fadlalla, Vf, Farah, Ma, Fernandez Vina, R, Ferro, A, Fischer, D, Flore, V, Foley, Dp, Gafoor, S, Gallo, S, Gaspardone, A, Gavrilescu, D, Gentiletti, A, Gilard, M, Giovannelli, F, Gonzalez Pacheco, I, Gonzalo, N, Grajek, S, Gurgel De Medeiros, Jp, Haine, S, Hakim, D, Hakim Vista, Jj, Hallani, H, Hamid, M, Helft, G, Heppell, Rm, Hernandez-Enriquez, M, Hlinomaz, O, Ho Choo, E, Huqi, A, Hurtado, Eo, Iakovou, I, Iosseliani, D, Janssens, L, Jean, M, Jensen, Jk, Jesudason, P, Jimenez Diaz, Va, Karchevsky, D, Karpovskii, A, Katsimagklis, G, Kereiakes, D, Kersanova, Nc, Kesavan, S, Khaled, H, Khalil, Sa, Kiatchoosakun, S, Kim, Ks, Kirma, C, Koltowski, L, Konteva, M, Kozinski, L, Kuehn, Cr, Kumar, S, Kyriakakis, Cg, Laanmets, P, Labrunie, A, Ladwiniec, A, Lai, G, Laine, M, Latib, A, Lattuca, B, Lazarevic, Am, Lee, Ks, Legrand, V, Leiva, G, Lester, N, Levchyshyna, O, Livia, G, Londero, Hf, Luha, O, Lupi, A, Lupkovics, G, Maaliki, S, Maeng, M, Mahr, Nc, Mantyla, P, Mariano, E, Marsit, N, Mcdonough, Tj, Medda, M, Mejia Viana, S, Merigo Azpir, Ca, Mitreski, S, Moreno, R, Moreu, J, Muehler, M, Muir, D, Munoz Molina, R, Musilli, N, Myc, J, Nadra, I, Nagy, Cd, Narayanan, A, Neugebauer, P, Nguyen, M, Nick, H, Nicolino, A, Obradovic, Sd, Paizis, I, Panagiotis, P, Park, Sd, Park, Sj, Pasquetto, G, Patel, D, Paunovic, D, Pedon, L, Pereira Machado, F, Pershukov, H, Petrou, E, Pinton, Fa, Preti, G, Puri, R, Pyxaras, Sa, Quintanilla, J, Rhouati, A, Ribeiro De Oliveira, I, Rivetti, L, Rodriguez, Ae, Rotevatn, S, Rubartelli, P, Sachdeva, R, Sanchez-Perez, H, Sangiorgi, G, Santoro, Gm, Saporito, F, Scappaticci, M, Schmermund, A, Schmidt, Je, Schmitz, T, Schneider, Ti, Schuchlenz, H, Sepulveda Varela, P, Shaw, E, Silva Marques, J, Skalidis, E, Slhessarenko, J, Spaulding, C, Stankovic, G, Suwannasom, P, Synetos, A, Szuster, E, Taha, S, Tavano, D, Tebet, M, Thury, A, Toutouzas, K, Triantafyllis, As, Tsikaderis, D, Tumscitz, C, Tzanogiorgis, I, Udovichenko, A, Ulrike, N, Unikas, R, Valerio, Mg, Van Mieghem, C, Vandendriessche, T, Vavlukis, M, Vigna, C, Vilar, Jv, Vizzari, G, Voudris, V, Wafa, S, Wagner, Dr, Wichter, T, Wiedemann, S, Williams, Pd, Woody, W, Yding, A, Zachow, G, Webster, M, Valgimigli, M., Costa, F., Byrne, R., Haude, M., Baumbach, A., Windecker, S., Aaroe, J., Aasa, M., Abdel-Salam, A. M., Alaarag, A. F., Accardi, R., Adel, A., Alcazar De La Torre, E., Alejos, R., Alfonso Jimenez, V., Alhashimi, H. M. M., Aljeboury, A., Almeida De Sousa, J., Almusawi, A., Alshaikha, M., Altaf, S., Altahmody, K. E. A., Alvarez Contreras, L. R., Amarasena, N., Amoroso, G., Anderson, R., Ando, G., Andrade, J., Andreou, A. Y., Angulo, J., Antonio, T., Aprigliano, G., Aquilina, M., Arafa, S. E. O., Aramberry, L., Arampatzis, C. A., Araujo, J. J., Asher, E., Ates, I., Athanasias, D., Auer, J., Auffret, V., Ayala, F. J., Baba, C., Baglioni, P., Bagur, R., Balam-Ortiz, E., Balducelli, M., Bam Pas, G., Barbash, I. M., Barbosa, A. H. P., Barbosa, R., Barnay, P., Barroso, L., Basti, A., Bax, M., Bayet, G., Beijk, M. A., Beltran, R., Berenguer Jofresa, A., Berroth, R., Berti, S., Berumen Dominguez, L. E., Bhasin, A., Bhaya, M., Bianco, M., Biasco, L., Bikicki, M., Bonarjee, V. V. S., Bonechi, F., Borges Santos, M., Boshev, M., Bouferrouk, A., Bounartzidi, M., Bousoula, E., Brie, D., Brtko, M., Brugaletta, S., Brull, D. J., Buchter, B., Buendia, R., Burzotta, F., Butz, T., Buzzetti, F., Bychowiec, B., Cadeddu, M., Campanile, A., Carneiro, J. G., Carrilho-Ferreira, P., Carrillo Guevara, J. E., Carter, A. J., Casal-Heredia, H., Castiglioni, B., Castro Fabiano, L., Cavalcante Silva, R., Cavalcanti De Oliveira, D., Cavalcanti, R. C., Cavazza, C., Centemero, M. P., Chabane, H. K., Chamie, D., Chatzis, D., Chaves, A. J., Cheng, S., Chinchilla, H., Ciabatti, N., Cirillo, P., Citaku, H., Claeys, M. J., Clifford, C., Coceani, M., Coggiola, J., Cohen, D. J., Conway, D. S. G., Cornelis, K., Coroleu, S. F., Corral, J. M., Cortese, B., Coskun, U., Costa, R. A., Coste, P., Coufal, Z., Cox, S., Cozma, A., Crean, P., Crenshaw, M. H., Cristian, U., Cruz-Alvarado, J. E., Cuculi, F., Cuenza, L., Cyrne Carvalho, H., D'Ascenzo, F., D'Urbano, M., Damonte, A., Dan Florin, F., Dana, A., Dangoisse, V., De Backer, O., De Cock, D., De Vita, M., Debski, A., Delgado, A., Devadathan, S., Dhamrait, S., Di Lorenzo, E., Di Serafino, D., Diego-Nieto, A., Dievart, F., Diez, J. L., Dimitriadis, K., Dina, C., Doerner, O., Donahue, M., Donis, J., Drieghe, B., Drissi, M. F., Du Fretay, H., Dziewierz, A., Echavarria-Pinto, M., Echeverria Romero, R. G., Economou, F., Eftychiou, C., Egdell, R., El Hosieny, A., El Meguid, K., Elabbassi, W., Elesgerli, S., Elghetany, H., Elizondo, J. C., Elkahlout, A., Elrowiny, R., Elserafy, A. S., Emam, A., Emara, A., Emmanouil, P., Ercilla, J., Erglis, A., Eslam Taha, E., Esmaeil, S., Esposito, G., Ettori, F., Eugenio, N., Everaert, B., Ezquerra Aguilar, W., Falu, R., Farag, E., Farjalla, J., Feldman, L., Feldman, M., Felice, H., Fernandez-Nofrerias, E., Fernandez-Rodriguez, D., Ferranti, F., Ferreira, Q., Ferrone, M., Fleischmann, C., Flessas, D., Formigli, D., Fozilov, H., Fraccaro, C., Freitas, J. O., Fresco, C., Fridrich, V., Furmaniuk, J., Gagnor, A., Galasso, G., Galeazzi, G. L., Galli, S., Galvez Villacorta, V., Gandolfo, C., Garcia, E., Garcia-Blas, S., Garducci, S., Garg, S., Garro, N., Gatto, L., Georgiou, M. G., Ghanem, I., Ghose, T., Giacchi, G., Giang, P. T., Giesler, T., Giovino, M., Girardi, P., Girasis, C., Giunio, L., Giustino, G., Glatthor, C., Glogar, H. D., Golledge, P., Gomez Moreno, J., Gomez Recio, M., Gommeaux, A., Grantalis, G., Greco, F., Grundeken, M. J., Grunert, S., Gudmundsdottir, I., Guenoun, M., Guerios, E., Gupta, R., Gupta, S., Gutierrez, C., Hafeez, I., Halvorsen, S., Hamed Hussein, G. A., Hammoudeh, A., Hansen, P. R., Harb, S., Hawas, J. M., Hayrapetyan, H., Heintzen, M. P., Hengstenberg, C., Herity, N., Hernandez, F., Heyse, A., Hicham, D., Hildick-Smith, D., Hill, J., Hillani, A., Hiltrop, N., Hiramori, A., Hobson, A. R., Homan, D. J., Hooda, A., Ielasi, A., Ierna, S., Iftikhar, A. K., Ilic, I., Imai, Y., Imperadore, F., Indolfi, C., Iorga, V., Ipek, E., Ito, S., Jacksch, R., Jae-Sik, J., James, S., Jamshidi, P., Jerbi, J., Jimenez Quevedo, P., Jimenez-Navarro, M., Jimenez-Santos, M., Jin, Q. H., Joksas, V., Jovic, D., Junejo, S., Kallel, R., Kamal, A., Kamiya, H., Kannan, D., Kantaria, M., Kapetanopoulos, A., Kara Ali, B., Karjalainen, P. P., Karthikeyan, V. J., Kato, R., Katsikis, A., Kefer, J., Keta, D., Ketteler, T., Khan, M., Kharlamov, A., Kinani, A., Kinani, T., Kinnaird, T., Kislo, A., Kiviniemi, T., Kleiban, A., Kluck, B., Kocayigit, I., Kokis, A., Komiyama, N., Konstantinos, L., Kordalis, A., Kozak, M., Krecki, R., Kristensen, S. D., Krizanic, F., Krsticevic, L., Kuex, H., Kukreja, N., Kulic, M., Kulikovskikh, Y. V., Kulkarni, P., Kumar, N., Kumar Soni, A., Kuzmenko, E., L'Allier, P. L., Langner, O., Lapin, O., Lauer, B., Leclercq, F., Leibundgut, G., Leon Aliz, E., Leon, C., Leon, K., Leoncini, M., Leone, A. M., Leroux, L., Lesiak, M., Letilovic, T., Lev, E., Linares Vicente, J. A., Lindsay, S., Loh, P. H., Loncar, G., Loo, B., Lopez, M. B., Lopez-Cuellar, J., Lozano, I., Luigia, P., Lunde, K., Lyczywek, M., Macdougall, D., Mafrici, A., Magni, V., Magro, M., Mainar, V., Makarovic, Z., Malik, N., Maly, M., Mansour, S., Marenco, R. E., Maresta, A., Marinho, G. E., Marino, R. L., Marinucci, L., Martins, H. C., Martins, J., Mashayekhi, K., Masood, A., Maurer, E., Mavrogianni, A. D., Mazurek, T., Medina, A., Mehilli, J., Mellwig, K. P., Mendez, M., Mendiz, O. A., Meneses, A., Mercado, L. A., Mereuta, A., Mezzapelle, G., Milanovic, N., Mohamed, S. M., Mohanad, A., Mohanty, A., Moorthy, N., Morales, F. J., More, R., Moreno Samos, J. C., Moreno-Martinez, F. L., Moscato, F., Mossmann, M., Mrevlje, B., Muller-Eichelberg, A., Musumeci, G., Nadir Khan, M., Najim, S., Nakamura, S., Nakao, F., Naveri, H., Negus, B., Nerla, R., Nguyen, H. T., Niess, G. S., Nikas, D. N., Niroomand, F., Niva, J., Nogueira, J. W., Nombela-Franco, L., Notrica, M., Nouri, B., Nugue, O., Nunes, G. L., Ober, M., Ochoa, J., Oh, J. H., Ojeda, S., Oktay Tureli, H., Olowe, Y., Oluseun, A., Opolski, G., Ornelas, C. E., Otasevic, P., Ozturk, A., Padilla, F., Pagny, J. Y., Paolantonio, D., Papaioannou, G. I., Parodi, G., Patil, S. N., Pavei, A., Pavia, A., Pavlidis, A., Pell, A., Percoco, G. F., Pernasetti, L. V., Pescoller, F., Petropoulakis, P., Piatti, L., Picardi, E., Pieroni, D. M., Pina, J., Pinheiro, L. F., Pinto, F. J., Pipa, J. L., Piroth, Z., Pisano, F., Podbregar, M., Polak, G., Polimeni, A., Postadzhiyan, A., Postu, M., Poulimenos, L. E., Pow Chon Long, F., Poyet, R., Pradhan, A., Predescu, L. M., Prida, X. E., Saad, A., Prog, R., Pulikal, D. G. A., Qiangzhong, P. I., Radu, M. D., Rajendran, D., Ram Anil Raj, M. R., Ramazzotti, V., Rapacciuolo, A., Ratib, K., Raungaard, B., Raviola, E., Reppas, E., Reyes, J. A., Rezek, M., Riess, G. J., Rifaie, O., Rigattieri, S., Rissanen, T., Ristic, A. D., Rittger, H., Roberts, J., Rodriguez Saavedra, A., Roik, M., Roshan Rao, K., Routledge, H., Rubboli, A., Rudolph, T., Rudzitis, A., Ruiters, A., Ruiz Ros, J. A., Ruiz-Garcia, J., Ruiz-Nodar, J. M., Sabate, M., Sabnis, G., Sabouret, P., Sacra, C., Saghatelyan, M., Sahin, M., Said, S., Salachas, A. J., Salas Llamas, J. P., Salih, A., Sanchez, O. D., Sanchez-Gila, J., Sanchez-Perez, I., Santarelli, A., Sardovski, Sarenac, D., Sarma, J., Sarno, G., Savonitto, S., Sayied Abdullah, A., Schafer, A., Scherillo, M., Schneider, H., Schuhlen, H., Sciahbasi, A., Seca, L., Sedlon, P., Semenka, J., Serra, L. A., Sesana, M., Sethi, A., Sgueglia, G. A., Shaheen, S., Shahri, H., Sheiban, I., Shyu, K. G., Silva, C. E. F., Sionis, D., Siqueira, D. A., Siqueira, M. J., Smits, P., Sobhy, M., Sokolov, M., Soliman, S., Somani, A. N., Sridhar, G., Stakos, D., Stasek, J., Stefanini, G., Steigen, T. K., Stewart, Stipal, R., Stochino, M. L., Stoel, M. G., Subla, R. M., Suliman, A., Summaria, F., Stoyanov, N., Syed, A. A., Tanaka, Y., Tashani, A., Tauzin, S., Tawade, N., Tawfik, M., Tayeh, O., Terzic, I., Testa, L., Thevan, B., Thiam, M., Tiecco, F., Tierala, I., Tilea, I., Tilsted, H. H., Tomasik, A. R., Tonev, I., Torres Bosco, A., Tousek, P., Townend, J., Tran Ngoc, T., Triantafyllou, K., Tsigkas, G., Tsioufis, C., Turri, M., Tyligadis, G., Ugo, F., Ultramari, F. T., Urban, P., Uren, N., Uretsky, B. F., Uribe, C. E., Usman, B., Valadez Molina, F., Van Houwelingen, K. G., Vandormael, M., Varvarovsky, I., Vassilis, V., Velasquez, D., Verdoia, M., Vermeersch, P., Vidal-Perez, R., Vinesh, J., Violini, R., Vista, J. H., Vogt, F., Vogt, M., Vokac, D., Vom Dahl, J., Vranckx, P., Wahab, A., Wang, R., Wang, T. D., Wani, S., Weisz, S. H., Werner, G. S., Wilkinson, J. R., Wolf, A., Youssef, A., Yumoto, K., Zaderenko, N., Zaghloul Darwish, A. M., Zahn, R., Zaro, T., Zavalloni, D., Zbinden, R., Zekanovic, D., Zhang, B., Zhang, C., Zhang, Y. J., Zhonghan, N., Zingarelli, A., Zueco, J., Zuhairy, H., Abbate, A., Abdel Hamid, M., Abdelmegid, M. A. F., Acuna-Valerio, J., Adriaenssens, T., Agostoni, P., Aikot, H., Alameda, M., Alcaraz, H., Almendro-Delia, M., Altug Cakmak, H., Amir, A., Arjomand, A., Assomull, R., Atalar, E., Avramides, D., Aytek Simsek, M., Aznaouridis, K., Azpeitia, Y., Barnabas, C., Barsness, G. W., Bartorelli, A. L., Basoglu, A., Benezet, J., Benincasa, S., Berland, J., Berrocal, D. H., Bett, N., Boskovic, S., Brandao, V., Caporale, R., Caprotta, F., Carrabba, N., Cazaux, P., Cheniti, G., Chinchilla Calix, H., Chung, W. Y., Cicco, N. A., Cieza, T., Clapp, B., Commeau, P., Cuellar, C., De Benedictis, M., De La Torre Hernandez, J. M., De Vroey, F., Degertekin, M., Eberli, F. R., Eggebrecht, H., Ekicibasi, E., Elmaraghi, M., Elod, P., Ergene, A. O., Fadlalla, V. F., Farah, M. A., Fernandez Vina, R., Ferro, A., Fischer, D., Flore, V., Foley, D. P., Gafoor, S., Gallo, S., Gaspardone, A., Gavrilescu, D., Gentiletti, A., Gilard, M., Giovannelli, F., Gonzalez Pacheco, I., Gonzalo, N., Grajek, S., Gurgel De Medeiros, J. P., Haine, S., Hakim, D., Hakim Vista, J. J., Hallani, H., Hamid, M., Helft, G., Heppell, R. M., Hernandez-Enriquez, M., Hlinomaz, O., Ho Choo, E., Huqi, A., Hurtado, E. O., Iakovou, I., Iosseliani, D., Janssens, L., Jean, M., Jensen, J. K., Jesudason, P., Jimenez Diaz, V. A., Karchevsky, D., Karpovskii, A., Katsimagklis, G., Kereiakes, D., Kersanova, N. C., Kesavan, S., Khaled, H., Khalil, S. A., Kiatchoosakun, S., Kim, K. S., Kirma, C., Koltowski, L., Konteva, M., Kozinski, L., Kuehn, C. R., Kumar, S., Kyriakakis, C. G., Laanmets, P., Labrunie, A., Ladwiniec, A., Lai, G., Laine, M., Latib, A., Lattuca, B., Lazarevic, A. M., Lee, K. S., Legrand, V., Leiva, G., Lester, N., Levchyshyna, O., Livia, G., Londero, H. F., Luha, O., Lupi, A., Lupkovics, G., Maaliki, S., Maeng, M., Mahr, N. C., Mantyla, P., Mariano, E., Marsit, N., Mcdonough, T. J., Medda, M., Mejia Viana, S., Merigo Azpir, C. A., Mitreski, S., Moreno, R., Moreu, J., Muehler, M., Muir, D., Munoz Molina, R., Musilli, N., Myc, J., Nadra, I., Nagy, C. D., Narayanan, A., Neugebauer, P., Nguyen, M., Nick, H., Nicolino, A., Obradovic, S. D., Paizis, I., Panagiotis, P., Park, S. D., Park, S. J., Pasquetto, G., Patel, D., Paunovic, D., Pedon, L., Pereira Machado, F., Pershukov, H., Petrou, E., Pinton, F. A., Preti, G., Puri, R., Pyxaras, S. A., Quintanilla, J., Rhouati, A., Ribeiro De Oliveira, I., Rivetti, L., Rodriguez, A. E., Rotevatn, S., Rubartelli, P., Sachdeva, R., Sanchez-Perez, H., Sangiorgi, G., Santoro, G. M., Saporito, F., Scappaticci, M., Schmermund, A., Schmidt, J. E., Schmitz, T., Schneider, T. I., Schuchlenz, H., Sepulveda Varela, P., Shaw, E., Silva Marques, J., Skalidis, E., Slhessarenko, J., Spaulding, C., Stankovic, G., Suwannasom, P., Synetos, A., Szuster, E., Taha, S., Tavano, D., Tebet, M., Thury, A., Toutouzas, K., Triantafyllis, A. S., Tsikaderis, D., Tumscitz, C., Tzanogiorgis, I., Udovichenko, A., Ulrike, N., Unikas, R., Valerio, M. G., Van Mieghem, C., Vandendriessche, T., Vavlukis, M., Vigna, C., Vilar, J. V., Vizzari, G., Voudris, V., Wafa, S., Wagner, D. R., Wichter, T., Wiedemann, S., Williams, P. D., Woody, W., Yding, A., Zachow, G., and Webster, M.

Subjects
Male, medicine.medical_specialty, Time Factors, Percutaneous, Time Factor, Psychological intervention, Alternative medicine, MEDLINE, Practice Patterns, Drug Administration Schedule, acute coronary syndrome, Settore MED/11, Percutaneous Coronary Intervention, Pharmacotherapy, Drug Therapy, Physicians, Surveys and Questionnaires, drug-eluting stent, Humans, Surveys and Questionnaire, Medicine, Practice Patterns, Physicians', health care economics and organizations, clopidogrel, dual antiplatelet therapy (DAPT), stable coronary artery disease, Drug Therapy, Combination, Evidence-Based Medicine, Health Care Surveys, Platelet Aggregation Inhibitors, Practice Guidelines as Topic, Practice Patterns, Physicians, Treatment Outcome, Stents, business.industry, Platelet Aggregation Inhibitor, Coronary stenting, Evidence-based medicine, Middle Aged, Surgery, Clinical trial, Health Care Survey, Combination, Emergency medicine, Female, Cardiology and Cardiovascular Medicine, business, Human
Abstract

AIMS Our aim was to report on a survey initiated by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) concerning opinion on the evidence relating to dual antiplatelet therapy (DAPT) duration after coronary stenting. METHODS AND RESULTS Results from three randomised clinical trials were scheduled to be presented at the American Heart Association Scientific Sessions 2014 (AHA 2014). A web-based survey was distributed to all individuals registered in the EuroIntervention mailing list (n=15,200) both before and after AHA 2014. A total of 1,134 physicians responded to the first (i.e., before AHA 2014) and 542 to the second (i.e., after AHA 2014) survey. The majority of respondents interpreted trial results consistent with a substantial equipoise regarding the benefits and risks of an extended versus a standard DAPT strategy. Two respondents out of ten believed extended DAPT should be implemented in selected patients. After AHA 2014, 46.1% of participants expressed uncertainty about the available evidence on DAPT duration, and 40.0% the need for clinical guidance. CONCLUSIONS This EAPCI survey highlights considerable uncertainty within the medical community with regard to the optimal duration of DAPT after coronary stenting in the light of recent reported trial results. Updated recommendations for practising physicians to guide treatment decisions in routine clinical practice should be provided by international societies.

Published
2015

10. Management of a Difficult Airway Scenario in a Case of Hurler’s Syndrome with a D-Blade Video Laryngoscope.

Author

Thakkar, Keta D., Hrishi, Ajay P., Sethuraman, Manikandan, and Vimala, Smita

Abstract

Hurler’s syndrome is a rare genetic disease characterized by progressive multiorgan accumulation of glycosaminoglycans. It is associated with progressive craniofacial, skeletal, and cardiac involvement, which increases the risk of anesthesia. Patients with Hurler’s syndrome could present as the worst airway management problem an anesthesiologist could deal with due to abnormal upper airway anatomy and limited neck manipulation, owing to the atlantoaxial instability. We report a case of difficult airway scenario of a child with Hurler’s syndrome, leading to an apparent cannot ventilate cannot intubate scenario, which was managed successfully with the help of a C-MAC video laryngoscope with unique D-blade. In Hurler’s syndrome, C-MAC with D-blade is an excellent tool in establishing an airway in a pediatric difficult airway scenario. Moreover, D-blade C-MAC could be considered as the primary tool for establishing an airway in pediatric patients with Hurler’s syndrome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

11. Dual antiplatelet therapy duration after coronary stenting in clinical practice: Results of an EAPCI survey

Author

Valgimigli, M., Costa, F., Byrne, R., Haude, M., Baumbach, A., Windecker, S., Aaroe, J., Aasa, M., Abdel-Salam, A. M., Alaarag, A. F., Accardi, R., Adel, A., Alcazar De La Torre, E., Alejos, R., Alfonso Jimenez, V., Alhashimi, H. M. M., Aljeboury, A., Almeida De Sousa, J., Almusawi, A., Alshaikha, M., Altaf, S., Altahmody, K. E. A., Alvarez Contreras, L. R., Amarasena, N., Amoroso, G., Anderson, R., Ando, G., Andrade, J., Andreou, A. Y., Angulo, J., Antonio, T., Aprigliano, G., Aquilina, M., Arafa, S. E. O., Aramberry, L., Arampatzis, C. A., Araujo, J. J., Asher, E., Ates, I., Athanasias, D., Auer, J., Auffret, V., Ayala, F. J., Baba, C., Baglioni, P., Bagur, R., Balam-Ortiz, E., Balducelli, M., Bam Pas, G., Barbash, I. M., Barbosa, A. H. P., Barbosa, R., Barnay, P., Barroso, L., Basti, A., Bax, M., Bayet, G., Beijk, M. A., Beltran, R., Berenguer Jofresa, A., Berroth, R., Berti, S., Berumen Dominguez, L. E., Bhasin, A., Bhaya, M., Bianco, M., Biasco, L., Bikicki, M., Bonarjee, V. V. S., Bonechi, F., Borges Santos, M., Boshev, M., Bouferrouk, A., Bounartzidi, M., Bousoula, E., Brie, D., Brtko, M., Brugaletta, S., Brull, D. J., Buchter, B., Buendia, R., Burzotta, Francesco, Butz, T., Buzzetti, F., Bychowiec, B., Cadeddu, M., Campanile, A., Carneiro, J. G., Carrilho-Ferreira, P., Carrillo Guevara, J. E., Carter, A. J., Casal-Heredia, H., Castiglioni, B., Castro Fabiano, L., Cavalcante Silva, R., Cavalcanti De Oliveira, D., Cavalcanti, R. C., Cavazza, C., Centemero, M. P., Chabane, H. K., Chamie, D., Chatzis, D., Chaves, A. J., Cheng, S., Chinchilla, H., Ciabatti, N., Cirillo, P., Citaku, H., Claeys, M. J., Clifford, C., Coceani, M., Coggiola, J., Cohen, D. J., Conway, D. S. G., Cornelis, K., Coroleu, S. F., Corral, J. M., Cortese, B., Coskun, U., Costa, R. A., Coste, P., Coufal, Z., Cox, S., Cozma, A., Crean, P., Crenshaw, M. H., Cristian, U., Cruz-Alvarado, J. E., Cuculi, F., Cuenza, L., Cyrne Carvalho, H., D'Ascenzo, F., D'Urbano, M., Damonte, A., Dan Florin, F., Dana, A., Dangoisse, V., De Backer, O., De Cock, D., De Vita, M., Debski, A., Delgado, A., Devadathan, S., Dhamrait, S., Di Lorenzo, E., Di Serafino, D., Diego-Nieto, A., Dievart, F., Diez, J. L., Dimitriadis, K., Dina, C., Doerner, O., Donahue, M., Donis, J., Drieghe, B., Drissi, M. F., Du Fretay, H., Dziewierz, A., Echavarria-Pinto, M., Echeverria Romero, R. G., Economou, F., Eftychiou, C., Egdell, R., El Hosieny, A., El Meguid, K., Elabbassi, W., Elesgerli, S., Elghetany, H., Elizondo, J. C., Elkahlout, A., Elrowiny, R., Elserafy, A. S., Emam, A., Emara, A., Emmanouil, P., Ercilla, J., Erglis, A., Eslam Taha, E., Esmaeil, S., Esposito, G., Ettori, F., Eugenio, N., Everaert, B., Ezquerra Aguilar, W., Falu, R., Farag, E., Farjalla, J., Feldman, L., Feldman, M., Felice, H., Fernandez-Nofrerias, E., Fernandez-Rodriguez, D., Ferranti, F., Ferreira, Q., Ferrone, M., Fleischmann, C., Flessas, D., Formigli, D., Fozilov, H., Fraccaro, C., Freitas, J. O., Fresco, C., Fridrich, V., Furmaniuk, J., Gagnor, A., Galasso, G., Galeazzi, G. L., Galli, S., Galvez Villacorta, V., Gandolfo, C., Garcia, E., Garcia-Blas, S., Garducci, S., Garg, S., Garro, N., Gatto, L., Georgiou, M. G., Ghanem, I., Ghose, T., Giacchi, G., Giang, P. T., Giesler, T., Giovino, M., Girardi, P., Girasis, C., Giunio, L., Giustino, G., Glatthor, C., Glogar, H. D., Golledge, P., Gomez Moreno, J., Gomez Recio, M., Gommeaux, A., Grantalis, G., Greco, F., Grundeken, M. J., Grunert, S., Gudmundsdottir, I., Guenoun, M., Guerios, E., Gupta, R., Gupta, S., Gutierrez, C., Hafeez, I., Halvorsen, S., Hamed Hussein, G. A., Hammoudeh, A., Hansen, P. R., Harb, S., Hawas, J. M., Hayrapetyan, H., Heintzen, M. P., Hengstenberg, C., Herity, N., Hernandez, F., Heyse, A., Hicham, D., Hildick-Smith, D., Hill, J., Hillani, A., Hiltrop, N., Hiramori, A., Hobson, A. R., Homan, D. J., Hooda, A., Ielasi, A., Ierna, S., Iftikhar, A. K., Ilic, I., Imai, Y., Imperadore, F., Indolfi, C., Iorga, V., Ipek, E., Ito, S., Jacksch, R., Jae-Sik, J., James, S., Jamshidi, P., Jerbi, J., Jimenez Quevedo, P., Jimenez-Navarro, M., Jimenez-Santos, M., Jin, Q. H., Joksas, V., Jovic, D., Junejo, S., Kallel, R., Kamal, A., Kamiya, H., Kannan, D., Kantaria, M., Kapetanopoulos, A., Kara Ali, B., Karjalainen, P. P., Karthikeyan, V. J., Kato, R., Katsikis, A., Kefer, J., Keta, D., Ketteler, T., Khan, M., Kharlamov, A., Kinani, A., Kinani, T., Kinnaird, T., Kislo, A., Kiviniemi, T., Kleiban, A., Kluck, B., Kocayigit, I., Kokis, A., Komiyama, N., Konstantinos, L., Kordalis, A., Kozak, M., Krecki, R., Kristensen, S. D., Krizanic, F., Krsticevic, L., Kuex, H., Kukreja, N., Kulic, M., Kulikovskikh, Y. V., Kulkarni, P., Kumar, N., Kumar Soni, A., Kuzmenko, E., L'Allier, P. L., Langner, O., Lapin, O., Lauer, B., Leclercq, F., Leibundgut, G., Leon Aliz, E., Leon, C., Leon, K., Leoncini, M., Leone, A. M., Leroux, L., Lesiak, M., Letilovic, T., Lev, E., Linares Vicente, J. A., Lindsay, S., Loh, P. H., Loncar, G., Loo, B., Lopez, M. B., Lopez-Cuellar, J., Lozano, I., Luigia, P., Lunde, K., Lyczywek, M., Macdougall, D., Mafrici, A., Magni, V., Magro, M., Mainar, V., Makarovic, Z., Malik, N., Maly, M., Mansour, S., Marenco, R. E., Maresta, A., Marinho, G. E., Marino, R. L., Marinucci, L., Martins, H. C., Martins, J., Mashayekhi, K., Masood, A., Maurer, E., Mavrogianni, A. D., Mazurek, T., Medina, A., Mehilli, J., Mellwig, K. P., Mendez, M., Mendiz, O. A., Meneses, A., Mercado, L. A., Mereuta, A., Mezzapelle, G., Milanovic, N., Mohamed, S. M., Mohanad, A., Mohanty, A., Moorthy, N., Morales, F. J., More, R., Moreno Samos, J. C., Moreno-Martinez, F. L., Moscato, F., Mossmann, M., Mrevlje, B., Muller-Eichelberg, A., Musumeci, G., Nadir Khan, M., Najim, S., Nakamura, S., Nakao, F., Naveri, H., Negus, B., Nerla, R., Nguyen, H. T., Niess, G. S., Nikas, D. N., Niroomand, F., Niva, J., Nogueira, J. W., Nombela-Franco, L., Notrica, M., Nouri, B., Nugue, O., Nunes, G. L., Ober, M., Ochoa, J., Oh, J. H., Ojeda, S., Oktay Tureli, H., Olowe, Y., Oluseun, A., Opolski, G., Ornelas, C. E., Otasevic, P., Ozturk, A., Padilla, F., Pagny, J. Y., Paolantonio, D., Papaioannou, G. I., Parodi, G., Patil, S. N., Pavei, A., Pavia, A., Pavlidis, A., Pell, A., Percoco, G. F., Pernasetti, L. V., Pescoller, F., Petropoulakis, P., Piatti, L., Picardi, E., Pieroni, D. M., Pina, J., Pinheiro, L. F., Pinto, F. J., Pipa, J. L., Piroth, Z., Pisano, F., Podbregar, M., Polak, G., Polimeni, A., Postadzhiyan, A., Postu, M., Poulimenos, L. E., Pow Chon Long, F., Poyet, R., Pradhan, A., Predescu, L. M., Prida, X. E., Saad, A., Prog, R., Pulikal, D. G. A., Qiangzhong, P. I., Radu, M. D., Rajendran, D., Ram Anil Raj, M. R., Ramazzotti, V., Rapacciuolo, A., Ratib, K., Raungaard, B., Raviola, E., Reppas, E., Reyes, J. A., Rezek, M., Riess, G. J., Rifaie, O., Rigattieri, S., Rissanen, T., Ristic, A. D., Rittger, H., Roberts, J., Rodriguez Saavedra, A., Roik, M., Roshan Rao, K., Routledge, H., Rubboli, A., Rudolph, T., Rudzitis, A., Ruiters, A., Ruiz Ros, J. A., Ruiz-Garcia, J., Ruiz-Nodar, J. M., Sabate, M., Sabnis, G., Sabouret, P., Sacra, C., Saghatelyan, M., Sahin, M., Said, S., Salachas, A. J., Salas Llamas, J. P., Salih, A., Sanchez, O. D., Sanchez-Gila, J., Sanchez-Perez, I., Santarelli, A., Sardovski, Sarenac, D., Sarma, J., Sarno, G., Savonitto, S., Sayied Abdullah, A., Schafer, A., Scherillo, M., Schneider, H., Schuhlen, H., Sciahbasi, A., Seca, L., Sedlon, P., Semenka, J., Serra, L. A., Sesana, M., Sethi, A., Sgueglia, G. A., Shaheen, S., Shahri, H., Sheiban, I., Shyu, K. G., Silva, C. E. F., Sionis, D., Siqueira, D. A., Siqueira, M. J., Smits, P., Sobhy, M., Sokolov, M., Soliman, S., Somani, A. N., Sridhar, G., Stakos, D., Stasek, J., Stefanini, G., Steigen, T. K., Stewart, Stipal, R., Stochino, M. L., Stoel, M. G., Subla, R. M., Suliman, A., Summaria, F., Stoyanov, N., Syed, A. A., Tanaka, Y., Tashani, A., Tauzin, S., Tawade, N., Tawfik, M., Tayeh, O., Terzic, I., Testa, L., Thevan, B., Thiam, M., Tiecco, F., Tierala, I., Tilea, I., Tilsted, H. H., Tomasik, A. R., Tonev, I., Torres Bosco, A., Tousek, P., Townend, J., Tran Ngoc, T., Triantafyllou, K., Tsigkas, G., Tsioufis, C., Turri, M., Tyligadis, G., Ugo, F., Ultramari, F. T., Urban, P., Uren, N., Uretsky, B. F., Uribe, C. E., Usman, B., Valadez Molina, F., Van Houwelingen, K. G., Vandormael, M., Varvarovsky, I., Vassilis, V., Velasquez, D., Verdoia, M., Vermeersch, P., Vidal-Perez, R., Vinesh, J., Violini, R., Vista, J. H., Vogt, F., Vogt, M., Vokac, D., Vom Dahl, J., Vranckx, P., Wahab, A., Wang, R., Wang, T. D., Wani, S., Weisz, S. H., Werner, G. S., Wilkinson, J. R., Wolf, A., Youssef, A., Yumoto, K., Zaderenko, N., Zaghloul Darwish, A. M., Zahn, R., Zaro, T., Zavalloni, D., Zbinden, R., Zekanovic, D., Zhang, B., Zhang, C., Zhang, Y. J., Zhonghan, N., Zingarelli, A., Zueco, J., Zuhairy, H., Abbate, A., Abdel Hamid, M., Abdelmegid, M. A. F., Acuna-Valerio, J., Adriaenssens, T., Agostoni, P., Aikot, H., Alameda, M., Alcaraz, H., Almendro-Delia, M., Altug Cakmak, H., Amir, A., Arjomand, A., Assomull, R., Atalar, E., Avramides, D., Aytek Simsek, M., Aznaouridis, K., Azpeitia, Y., Barnabas, C., Barsness, G. W., Bartorelli, A. L., Basoglu, A., Benezet, J., Benincasa, S., Berland, J., Berrocal, D. H., Bett, N., Boskovic, S., Brandao, V., Caporale, R., Caprotta, F., Carrabba, N., Cazaux, P., Cheniti, G., Chinchilla Calix, H., Chung, W. Y., Cicco, N. A., Cieza, T., Clapp, B., Commeau, P., Cuellar, C., De Benedictis, M., De La Torre Hernandez, J. M., De Vroey, F., Degertekin, M., Eberli, F. R., Eggebrecht, H., Ekicibasi, E., Elmaraghi, M., Elod, P., Ergene, A. O., Fadlalla, V. F., Farah, M. A., Fernandez Vina, R., Ferro, A., Fischer, D., Flore, V., Foley, D. P., Gafoor, S., Gallo, S., Gaspardone, A., Gavrilescu, D., Gentiletti, A., Gilard, M., Giovannelli, F., Gonzalez Pacheco, I., Gonzalo, N., Grajek, S., Gurgel De Medeiros, J. P., Haine, S., Hakim, D., Hakim Vista, J. J., Hallani, H., Hamid, M., Helft, G., Heppell, R. M., Hernandez-Enriquez, M., Hlinomaz, O., Ho Choo, E., Huqi, A., Hurtado, E. O., Iakovou, I., Iosseliani, D., Janssens, L., Jean, M., Jensen, J. K., Jesudason, P., Jimenez Diaz, V. A., Karchevsky, D., Karpovskii, A., Katsimagklis, G., Kereiakes, D., Kersanova, N. C., Kesavan, S., Khaled, H., Khalil, S. A., Kiatchoosakun, S., Kim, K. S., Kirma, C., Koltowski, L., Konteva, M., Kozinski, L., Kuehn, C. R., Kumar, S., Kyriakakis, C. G., Laanmets, P., Labrunie, A., Ladwiniec, A., Lai, G., Laine, M., Latib, A., Lattuca, B., Lazarevic, A. M., Lee, K. S., Legrand, V., Leiva, G., Lester, N., Levchyshyna, O., Livia, G., Londero, H. F., Luha, O., Lupi, A., Lupkovics, G., Maaliki, S., Maeng, M., Mahr, N. C., Mantyla, P., Mariano, E., Marsit, N., Mcdonough, T. J., Medda, M., Mejia Viana, S., Merigo Azpir, C. A., Mitreski, S., Moreno, R., Moreu, J., Muehler, M., Muir, D., Munoz Molina, R., Musilli, N., Myc, J., Nadra, I., Nagy, C. D., Narayanan, A., Neugebauer, P., Nguyen, M., Nick, H., Nicolino, A., Obradovic, S. D., Paizis, I., Panagiotis, P., Park, S. D., Park, S. J., Pasquetto, G., Patel, D., Paunovic, D., Pedon, L., Pereira Machado, F., Pershukov, H., Petrou, E., Pinton, F. A., Preti, G., Puri, R., Pyxaras, S. A., Quintanilla, J., Rhouati, A., Ribeiro De Oliveira, I., Rivetti, L., Rodriguez, A. E., Rotevatn, S., Rubartelli, P., Sachdeva, R., Sanchez-Perez, H., Sangiorgi, G., Santoro, G. M., Saporito, F., Scappaticci, M., Schmermund, A., Schmidt, J. E., Schmitz, T., Schneider, T. I., Schuchlenz, H., Sepulveda Varela, P., Shaw, E., Silva Marques, J., Skalidis, E., Slhessarenko, J., Spaulding, C., Stankovic, G., Suwannasom, P., Synetos, A., Szuster, E., Taha, S., Tavano, D., Tebet, M., Thury, A., Toutouzas, K., Triantafyllis, A. S., Tsikaderis, D., Tumscitz, C., Tzanogiorgis, I., Udovichenko, A., Ulrike, N., Unikas, R., Valerio, M. G., Van Mieghem, C., Vandendriessche, T., Vavlukis, M., Vigna, C., Vilar, J. V., Vizzari, G., Voudris, V., Wafa, S., Wagner, D. R., Wichter, T., Wiedemann, S., Williams, P. D., Woody, W., Yding, A., Zachow, G., Webster, M., Burzotta F. (ORCID:0000-0002-6569-9401), Valgimigli, M., Costa, F., Byrne, R., Haude, M., Baumbach, A., Windecker, S., Aaroe, J., Aasa, M., Abdel-Salam, A. M., Alaarag, A. F., Accardi, R., Adel, A., Alcazar De La Torre, E., Alejos, R., Alfonso Jimenez, V., Alhashimi, H. M. M., Aljeboury, A., Almeida De Sousa, J., Almusawi, A., Alshaikha, M., Altaf, S., Altahmody, K. E. A., Alvarez Contreras, L. R., Amarasena, N., Amoroso, G., Anderson, R., Ando, G., Andrade, J., Andreou, A. Y., Angulo, J., Antonio, T., Aprigliano, G., Aquilina, M., Arafa, S. E. O., Aramberry, L., Arampatzis, C. A., Araujo, J. J., Asher, E., Ates, I., Athanasias, D., Auer, J., Auffret, V., Ayala, F. J., Baba, C., Baglioni, P., Bagur, R., Balam-Ortiz, E., Balducelli, M., Bam Pas, G., Barbash, I. M., Barbosa, A. H. P., Barbosa, R., Barnay, P., Barroso, L., Basti, A., Bax, M., Bayet, G., Beijk, M. A., Beltran, R., Berenguer Jofresa, A., Berroth, R., Berti, S., Berumen Dominguez, L. E., Bhasin, A., Bhaya, M., Bianco, M., Biasco, L., Bikicki, M., Bonarjee, V. V. S., Bonechi, F., Borges Santos, M., Boshev, M., Bouferrouk, A., Bounartzidi, M., Bousoula, E., Brie, D., Brtko, M., Brugaletta, S., Brull, D. J., Buchter, B., Buendia, R., Burzotta, Francesco, Butz, T., Buzzetti, F., Bychowiec, B., Cadeddu, M., Campanile, A., Carneiro, J. G., Carrilho-Ferreira, P., Carrillo Guevara, J. E., Carter, A. J., Casal-Heredia, H., Castiglioni, B., Castro Fabiano, L., Cavalcante Silva, R., Cavalcanti De Oliveira, D., Cavalcanti, R. C., Cavazza, C., Centemero, M. P., Chabane, H. K., Chamie, D., Chatzis, D., Chaves, A. J., Cheng, S., Chinchilla, H., Ciabatti, N., Cirillo, P., Citaku, H., Claeys, M. J., Clifford, C., Coceani, M., Coggiola, J., Cohen, D. J., Conway, D. S. G., Cornelis, K., Coroleu, S. F., Corral, J. M., Cortese, B., Coskun, U., Costa, R. A., Coste, P., Coufal, Z., Cox, S., Cozma, A., Crean, P., Crenshaw, M. H., Cristian, U., Cruz-Alvarado, J. E., Cuculi, F., Cuenza, L., Cyrne Carvalho, H., D'Ascenzo, F., D'Urbano, M., Damonte, A., Dan Florin, F., Dana, A., Dangoisse, V., De Backer, O., De Cock, D., De Vita, M., Debski, A., Delgado, A., Devadathan, S., Dhamrait, S., Di Lorenzo, E., Di Serafino, D., Diego-Nieto, A., Dievart, F., Diez, J. L., Dimitriadis, K., Dina, C., Doerner, O., Donahue, M., Donis, J., Drieghe, B., Drissi, M. F., Du Fretay, H., Dziewierz, A., Echavarria-Pinto, M., Echeverria Romero, R. G., Economou, F., Eftychiou, C., Egdell, R., El Hosieny, A., El Meguid, K., Elabbassi, W., Elesgerli, S., Elghetany, H., Elizondo, J. C., Elkahlout, A., Elrowiny, R., Elserafy, A. S., Emam, A., Emara, A., Emmanouil, P., Ercilla, J., Erglis, A., Eslam Taha, E., Esmaeil, S., Esposito, G., Ettori, F., Eugenio, N., Everaert, B., Ezquerra Aguilar, W., Falu, R., Farag, E., Farjalla, J., Feldman, L., Feldman, M., Felice, H., Fernandez-Nofrerias, E., Fernandez-Rodriguez, D., Ferranti, F., Ferreira, Q., Ferrone, M., Fleischmann, C., Flessas, D., Formigli, D., Fozilov, H., Fraccaro, C., Freitas, J. O., Fresco, C., Fridrich, V., Furmaniuk, J., Gagnor, A., Galasso, G., Galeazzi, G. L., Galli, S., Galvez Villacorta, V., Gandolfo, C., Garcia, E., Garcia-Blas, S., Garducci, S., Garg, S., Garro, N., Gatto, L., Georgiou, M. G., Ghanem, I., Ghose, T., Giacchi, G., Giang, P. T., Giesler, T., Giovino, M., Girardi, P., Girasis, C., Giunio, L., Giustino, G., Glatthor, C., Glogar, H. D., Golledge, P., Gomez Moreno, J., Gomez Recio, M., Gommeaux, A., Grantalis, G., Greco, F., Grundeken, M. J., Grunert, S., Gudmundsdottir, I., Guenoun, M., Guerios, E., Gupta, R., Gupta, S., Gutierrez, C., Hafeez, I., Halvorsen, S., Hamed Hussein, G. A., Hammoudeh, A., Hansen, P. R., Harb, S., Hawas, J. M., Hayrapetyan, H., Heintzen, M. P., Hengstenberg, C., Herity, N., Hernandez, F., Heyse, A., Hicham, D., Hildick-Smith, D., Hill, J., Hillani, A., Hiltrop, N., Hiramori, A., Hobson, A. R., Homan, D. J., Hooda, A., Ielasi, A., Ierna, S., Iftikhar, A. K., Ilic, I., Imai, Y., Imperadore, F., Indolfi, C., Iorga, V., Ipek, E., Ito, S., Jacksch, R., Jae-Sik, J., James, S., Jamshidi, P., Jerbi, J., Jimenez Quevedo, P., Jimenez-Navarro, M., Jimenez-Santos, M., Jin, Q. H., Joksas, V., Jovic, D., Junejo, S., Kallel, R., Kamal, A., Kamiya, H., Kannan, D., Kantaria, M., Kapetanopoulos, A., Kara Ali, B., Karjalainen, P. P., Karthikeyan, V. J., Kato, R., Katsikis, A., Kefer, J., Keta, D., Ketteler, T., Khan, M., Kharlamov, A., Kinani, A., Kinani, T., Kinnaird, T., Kislo, A., Kiviniemi, T., Kleiban, A., Kluck, B., Kocayigit, I., Kokis, A., Komiyama, N., Konstantinos, L., Kordalis, A., Kozak, M., Krecki, R., Kristensen, S. D., Krizanic, F., Krsticevic, L., Kuex, H., Kukreja, N., Kulic, M., Kulikovskikh, Y. V., Kulkarni, P., Kumar, N., Kumar Soni, A., Kuzmenko, E., L'Allier, P. L., Langner, O., Lapin, O., Lauer, B., Leclercq, F., Leibundgut, G., Leon Aliz, E., Leon, C., Leon, K., Leoncini, M., Leone, A. M., Leroux, L., Lesiak, M., Letilovic, T., Lev, E., Linares Vicente, J. A., Lindsay, S., Loh, P. H., Loncar, G., Loo, B., Lopez, M. B., Lopez-Cuellar, J., Lozano, I., Luigia, P., Lunde, K., Lyczywek, M., Macdougall, D., Mafrici, A., Magni, V., Magro, M., Mainar, V., Makarovic, Z., Malik, N., Maly, M., Mansour, S., Marenco, R. E., Maresta, A., Marinho, G. E., Marino, R. L., Marinucci, L., Martins, H. C., Martins, J., Mashayekhi, K., Masood, A., Maurer, E., Mavrogianni, A. D., Mazurek, T., Medina, A., Mehilli, J., Mellwig, K. P., Mendez, M., Mendiz, O. A., Meneses, A., Mercado, L. A., Mereuta, A., Mezzapelle, G., Milanovic, N., Mohamed, S. M., Mohanad, A., Mohanty, A., Moorthy, N., Morales, F. J., More, R., Moreno Samos, J. C., Moreno-Martinez, F. L., Moscato, F., Mossmann, M., Mrevlje, B., Muller-Eichelberg, A., Musumeci, G., Nadir Khan, M., Najim, S., Nakamura, S., Nakao, F., Naveri, H., Negus, B., Nerla, R., Nguyen, H. T., Niess, G. S., Nikas, D. N., Niroomand, F., Niva, J., Nogueira, J. W., Nombela-Franco, L., Notrica, M., Nouri, B., Nugue, O., Nunes, G. L., Ober, M., Ochoa, J., Oh, J. H., Ojeda, S., Oktay Tureli, H., Olowe, Y., Oluseun, A., Opolski, G., Ornelas, C. E., Otasevic, P., Ozturk, A., Padilla, F., Pagny, J. Y., Paolantonio, D., Papaioannou, G. I., Parodi, G., Patil, S. N., Pavei, A., Pavia, A., Pavlidis, A., Pell, A., Percoco, G. F., Pernasetti, L. V., Pescoller, F., Petropoulakis, P., Piatti, L., Picardi, E., Pieroni, D. M., Pina, J., Pinheiro, L. F., Pinto, F. J., Pipa, J. L., Piroth, Z., Pisano, F., Podbregar, M., Polak, G., Polimeni, A., Postadzhiyan, A., Postu, M., Poulimenos, L. E., Pow Chon Long, F., Poyet, R., Pradhan, A., Predescu, L. M., Prida, X. E., Saad, A., Prog, R., Pulikal, D. G. A., Qiangzhong, P. I., Radu, M. D., Rajendran, D., Ram Anil Raj, M. R., Ramazzotti, V., Rapacciuolo, A., Ratib, K., Raungaard, B., Raviola, E., Reppas, E., Reyes, J. A., Rezek, M., Riess, G. J., Rifaie, O., Rigattieri, S., Rissanen, T., Ristic, A. D., Rittger, H., Roberts, J., Rodriguez Saavedra, A., Roik, M., Roshan Rao, K., Routledge, H., Rubboli, A., Rudolph, T., Rudzitis, A., Ruiters, A., Ruiz Ros, J. A., Ruiz-Garcia, J., Ruiz-Nodar, J. M., Sabate, M., Sabnis, G., Sabouret, P., Sacra, C., Saghatelyan, M., Sahin, M., Said, S., Salachas, A. J., Salas Llamas, J. P., Salih, A., Sanchez, O. D., Sanchez-Gila, J., Sanchez-Perez, I., Santarelli, A., Sardovski, Sarenac, D., Sarma, J., Sarno, G., Savonitto, S., Sayied Abdullah, A., Schafer, A., Scherillo, M., Schneider, H., Schuhlen, H., Sciahbasi, A., Seca, L., Sedlon, P., Semenka, J., Serra, L. A., Sesana, M., Sethi, A., Sgueglia, G. A., Shaheen, S., Shahri, H., Sheiban, I., Shyu, K. G., Silva, C. E. F., Sionis, D., Siqueira, D. A., Siqueira, M. J., Smits, P., Sobhy, M., Sokolov, M., Soliman, S., Somani, A. N., Sridhar, G., Stakos, D., Stasek, J., Stefanini, G., Steigen, T. K., Stewart, Stipal, R., Stochino, M. L., Stoel, M. G., Subla, R. M., Suliman, A., Summaria, F., Stoyanov, N., Syed, A. A., Tanaka, Y., Tashani, A., Tauzin, S., Tawade, N., Tawfik, M., Tayeh, O., Terzic, I., Testa, L., Thevan, B., Thiam, M., Tiecco, F., Tierala, I., Tilea, I., Tilsted, H. H., Tomasik, A. R., Tonev, I., Torres Bosco, A., Tousek, P., Townend, J., Tran Ngoc, T., Triantafyllou, K., Tsigkas, G., Tsioufis, C., Turri, M., Tyligadis, G., Ugo, F., Ultramari, F. T., Urban, P., Uren, N., Uretsky, B. F., Uribe, C. E., Usman, B., Valadez Molina, F., Van Houwelingen, K. G., Vandormael, M., Varvarovsky, I., Vassilis, V., Velasquez, D., Verdoia, M., Vermeersch, P., Vidal-Perez, R., Vinesh, J., Violini, R., Vista, J. H., Vogt, F., Vogt, M., Vokac, D., Vom Dahl, J., Vranckx, P., Wahab, A., Wang, R., Wang, T. D., Wani, S., Weisz, S. H., Werner, G. S., Wilkinson, J. R., Wolf, A., Youssef, A., Yumoto, K., Zaderenko, N., Zaghloul Darwish, A. M., Zahn, R., Zaro, T., Zavalloni, D., Zbinden, R., Zekanovic, D., Zhang, B., Zhang, C., Zhang, Y. J., Zhonghan, N., Zingarelli, A., Zueco, J., Zuhairy, H., Abbate, A., Abdel Hamid, M., Abdelmegid, M. A. F., Acuna-Valerio, J., Adriaenssens, T., Agostoni, P., Aikot, H., Alameda, M., Alcaraz, H., Almendro-Delia, M., Altug Cakmak, H., Amir, A., Arjomand, A., Assomull, R., Atalar, E., Avramides, D., Aytek Simsek, M., Aznaouridis, K., Azpeitia, Y., Barnabas, C., Barsness, G. W., Bartorelli, A. L., Basoglu, A., Benezet, J., Benincasa, S., Berland, J., Berrocal, D. H., Bett, N., Boskovic, S., Brandao, V., Caporale, R., Caprotta, F., Carrabba, N., Cazaux, P., Cheniti, G., Chinchilla Calix, H., Chung, W. Y., Cicco, N. A., Cieza, T., Clapp, B., Commeau, P., Cuellar, C., De Benedictis, M., De La Torre Hernandez, J. M., De Vroey, F., Degertekin, M., Eberli, F. R., Eggebrecht, H., Ekicibasi, E., Elmaraghi, M., Elod, P., Ergene, A. O., Fadlalla, V. F., Farah, M. A., Fernandez Vina, R., Ferro, A., Fischer, D., Flore, V., Foley, D. P., Gafoor, S., Gallo, S., Gaspardone, A., Gavrilescu, D., Gentiletti, A., Gilard, M., Giovannelli, F., Gonzalez Pacheco, I., Gonzalo, N., Grajek, S., Gurgel De Medeiros, J. P., Haine, S., Hakim, D., Hakim Vista, J. J., Hallani, H., Hamid, M., Helft, G., Heppell, R. M., Hernandez-Enriquez, M., Hlinomaz, O., Ho Choo, E., Huqi, A., Hurtado, E. O., Iakovou, I., Iosseliani, D., Janssens, L., Jean, M., Jensen, J. K., Jesudason, P., Jimenez Diaz, V. A., Karchevsky, D., Karpovskii, A., Katsimagklis, G., Kereiakes, D., Kersanova, N. C., Kesavan, S., Khaled, H., Khalil, S. A., Kiatchoosakun, S., Kim, K. S., Kirma, C., Koltowski, L., Konteva, M., Kozinski, L., Kuehn, C. R., Kumar, S., Kyriakakis, C. G., Laanmets, P., Labrunie, A., Ladwiniec, A., Lai, G., Laine, M., Latib, A., Lattuca, B., Lazarevic, A. M., Lee, K. S., Legrand, V., Leiva, G., Lester, N., Levchyshyna, O., Livia, G., Londero, H. F., Luha, O., Lupi, A., Lupkovics, G., Maaliki, S., Maeng, M., Mahr, N. C., Mantyla, P., Mariano, E., Marsit, N., Mcdonough, T. J., Medda, M., Mejia Viana, S., Merigo Azpir, C. A., Mitreski, S., Moreno, R., Moreu, J., Muehler, M., Muir, D., Munoz Molina, R., Musilli, N., Myc, J., Nadra, I., Nagy, C. D., Narayanan, A., Neugebauer, P., Nguyen, M., Nick, H., Nicolino, A., Obradovic, S. D., Paizis, I., Panagiotis, P., Park, S. D., Park, S. J., Pasquetto, G., Patel, D., Paunovic, D., Pedon, L., Pereira Machado, F., Pershukov, H., Petrou, E., Pinton, F. A., Preti, G., Puri, R., Pyxaras, S. A., Quintanilla, J., Rhouati, A., Ribeiro De Oliveira, I., Rivetti, L., Rodriguez, A. E., Rotevatn, S., Rubartelli, P., Sachdeva, R., Sanchez-Perez, H., Sangiorgi, G., Santoro, G. M., Saporito, F., Scappaticci, M., Schmermund, A., Schmidt, J. E., Schmitz, T., Schneider, T. I., Schuchlenz, H., Sepulveda Varela, P., Shaw, E., Silva Marques, J., Skalidis, E., Slhessarenko, J., Spaulding, C., Stankovic, G., Suwannasom, P., Synetos, A., Szuster, E., Taha, S., Tavano, D., Tebet, M., Thury, A., Toutouzas, K., Triantafyllis, A. S., Tsikaderis, D., Tumscitz, C., Tzanogiorgis, I., Udovichenko, A., Ulrike, N., Unikas, R., Valerio, M. G., Van Mieghem, C., Vandendriessche, T., Vavlukis, M., Vigna, C., Vilar, J. V., Vizzari, G., Voudris, V., Wafa, S., Wagner, D. R., Wichter, T., Wiedemann, S., Williams, P. D., Woody, W., Yding, A., Zachow, G., Webster, M., and Burzotta F. (ORCID:0000-0002-6569-9401)

Abstract

Aims: Our aim was to report on a survey initiated by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) concerning opinion on the evidence relating to dual antiplatelet therapy (DAPT) duration after coronary stenting. Methods and results: Results from three randomised clinical trials were scheduled to be presented at the American Heart Association Scientific Sessions 2014 (AHA 2014). A web-based survey was distributed to all individuals registered in the EuroIntervention mailing list (n=15,200) both before and after AHA 2014. A total of 1,134 physicians responded to the first (i.e., before AHA 2014) and 542 to the second (i.e., after AHA 2014) survey. The majority of respondents interpreted trial results consistent with a substantial equipoise regarding the benefits and risks of an extended versus a standard DAPT strategy. Two respondents out of ten believed extended DAPT should be implemented in selected patients. After AHA 2014, 46.1% of participants expressed uncertainty about the available evidence on DAPT duration, and 40.0% the need for clinical guidance. Conclusions: This EAPCI survey highlights considerable uncertainty within the medical community with regard to the optimal duration of DAPT after coronary stenting in the light of recent reported trial results. Updated recommendations for practising physicians to guide treatment decisions in routine clinical practice should be provided by international societies.

Published
2015

12. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers

Author

Eric M, Reiman, Jennifer A, Webster, Amanda J, Myers, John, Hardy, Travis, Dunckley, Victoria L, Zismann, Keta D, Joshipura, John V, Pearson, Diane, Hu-Lince, Matthew J, Huentelman, David W, Craig, Keith D, Coon, Winnie S, Liang, RiLee H, Herbert, Thomas, Beach, Kristen C, Rohrer, Alice S, Zhao, Doris, Leung, Leslie, Bryden, Lauren, Marlowe, Mona, Kaleem, Diego, Mastroeni, Andrew, Grover, Christopher B, Heward, Rivka, Ravid, Joseph, Rogers, Michael L, Hutton, Stacey, Melquist, Ron C, Petersen, Gene E, Alexander, Richard J, Caselli, Walter, Kukull, Andreas, Papassotiropoulos, and Dietrich A, Stephan

Subjects
Brain Chemistry, Genetic Markers, Apolipoprotein E4, DNA Mutational Analysis, Brain, Neurofibrillary Tangles, tau Proteins, Polymorphism, Single Nucleotide, Article, Gene Expression Regulation, Gene Frequency, Haplotypes, Alzheimer Disease, Risk Factors, Cell Line, Tumor, Mutation, Humans, Genetic Predisposition to Disease, Genetic Testing, Phosphorylation, Adaptor Proteins, Signal Transducing
Abstract

The apolipoprotein E (APOE) epsilon4 allele is the best established genetic risk factor for late-onset Alzheimer's disease (LOAD). We conducted genome-wide surveys of 502,627 single-nucleotide polymorphisms (SNPs) to characterize and confirm other LOAD susceptibility genes. In epsilon4 carriers from neuropathologically verified discovery, neuropathologically verified replication, and clinically characterized replication cohorts of 1411 cases and controls, LOAD was associated with six SNPs from the GRB-associated binding protein 2 (GAB2) gene and a common haplotype encompassing the entire GAB2 gene. SNP rs2373115 (p = 9 x 10(-11)) was associated with an odds ratio of 4.06 (confidence interval 2.81-14.69), which interacts with APOE epsilon4 to further modify risk. GAB2 was overexpressed in pathologically vulnerable neurons; the Gab2 protein was detected in neurons, tangle-bearing neurons, and dystrophic neuritis; and interference with GAB2 gene expression increased tau phosphorylation. Our findings suggest that GAB2 modifies LOAD risk in APOE epsilon4 carriers and influences Alzheimer's neuropathology.

Published
2007

13. Re-animating orality: the design for a new translation of the Bible into Sesotho

Author

Makutoane, Tshokolo Johannes, Naude, J. A., Keta, D. T., Makutoane, Tshokolo Johannes, Naude, J. A., and Keta, D. T.

Abstract

English: The Sesotho community has proved an avid religious (Christian) audience for more than a century. Two Sesotho translations of the Bible, the Old Translation of 1909 and the New Translation of 1989, are used by Sesotho-speaking people. The former seems to be complex and difficult to its users (both those who can and those who cannot read the written text) due to the following reasons: (i) its adherence to a word-for-word philosophy of translation (reflecting the Biblical Hebrew structure in Sesotho in terms of lexical items for the Lord, such as Jehova (1909) which is Hebrew instead of Morena (1989), and (ii) features of colonial interference during the translation of the Bible (e.g. the use of the Afrikaans loanword teronkong instead of the indigenous Sesotho word tjhankaneng for 'prison'). The primary concern of the later version is meaning and readability, but it was not well accepted by much of its prospective readership. Others would say the translation was much easier to read, and therefore had lost its authenticity. Both translations lean heavily on the reader's ability to understand a written text. They constitute a very serious problem in a religious community made up of members not able to read the written text. This was proven by a preliminary study of illiteracy which was undertaken by the researcher in Bloemfontein's Sesotho-speaking congregations in 2007. The study indicated that 11% of the church members cannot read or write; this figure would presumably be higher in the rural communities. One must also take notice of the fact that in the remaining 89% of religious communities there are Bible readers who still find it difficult to master the content of the Bible due to the complexity of the vocabulary and language structure of the text when read aloud. This means a Bible translation adapted to the needs of the specific target audience is needed. The problem that was investigated for this thesis was: How can the Bible be translated to fulfill th, Afrikaans: Die Sesotho gemeenskap het hulself as 'n ware Christen religieuse gehoor oor 'n tydperk van honderdjaar bewys. Die Sesothogemeenskap gebruik twee Sesotho Bybelvertalings naamlik die Ou Sesotho Vertaling van 1909 en die Nuwe Sesotho Vertaling van 1989. Die eerste vertaling (1909) blyk of dit moeilik verstaanbaar is vir sy gebruikers (beide die wat die geskrewe teks kan lees en die wat dit nie kan lees nie) vanweë die volgende redes: (i) Dit steun op 'n word-vir-woord vertaalfilosofie (die reflektering van die Bybelhebreeuse stuktuur in Sesotho in terme van die leksikale terme vir Here soos byvoorbeeld Jehova (1909) - in Hebreeus in plaas van Morena (1989), en (ii) elemente van koloniale intervensie gedurende die vertaling van die Bybel (bv. die gebruik van die Afrikaanse leenwoord teronkong in plaas van die inheemse Sesothowoord tjhankaneng vir gevangenis/tronk). Die primêre probleem met die latere uitgawe is betekenis asook leesbaarheid. Hierdie vertaling is nie goed ontvang deur sy voornemende lesers nie. Ander meen dat hierdie vertaling heel makliker lees en daarvoor sy outensiteit verloor het. Beide vertalings leen sterk op die leser se vermoë om die geskrewe teks te verstaan. Dit konstitueer 'n baie ernstige probleem in 'n religieuse gemeenskap bestaande uit lede wat nie die geskrewe teks kan lees nie. Dit word bewys deur 'n prelimenêre studie van geletterdheid in gemeentes van Bloemfontein in 2007. Hierdie studie, opgestel deur die navorser, toon dat 11% van die lidmate van die kerk nie kan lees of skryf nie. Daar word verder gemeen dat die situasie veel groter is in die plattelandse gemeenskappe. Daar moet verder gelet word op die feit dat die oorblywende 89% van die lidmate van die kerk Bybellesers is wat dit steeds moeilik vind om die inhoud van die Bybel te bemeester vanweë die kompleksiteit van die terminologie en taalstruktuur van die teks wanneer dit hardop gelees word. Dit beteken dat 'n Bybelvertaling gerig op die behoeftes van 'n spesifieke, Sesotho: Setjhaba sa Basotho se netefaditse Bokreste ba bona ka dilemo tse fetang lekgolo. Ba sebedisa diphetolelo tse pedi e leng ya 1909 mmoho le ya 1989. Phetolelo ya pele (1909) e bonahala e le thata ho utlwisiseheng ho babadi ba yona ka tlasa mabaka a na a latelang: (i) Ho itshetleheng ha yona mokgweng wa phetolelo ya lentswe ka lentswe ho tswa puong tsa .motheo. Mohlala wa sena 0 bonahala ha phetolelo ya 1909 e ntse e bontsha popeho ya puo ya motheo ho mantswe a tshwanang le Jehova e leng Seheberu bakeng sa hore e sebedise Morena, (ii) Tshebediso ya puo tse ding nakong ya phetolelo, jwaloka ho sebedisa lentswe teronkong (Seafrikanse) bakeng sa tjhankaneng, jwalojwalo. Sepheo sa phetolelo ya bobedi (1989) ke moelelo le ho bala. Phetolelo ena ha ya ka ya amohelwa ke babadi ba Beibele ya Sesotho. Ba bang ba ne ba re e bonoio haholo, mme e lahlehetswe ke matla a Lentswe la Modimo, jwalojwalo. Diphetolelo ka bobedi di ngotswe bakeng sa hore di balwe. Sena ke tsietsi ho setjhaba sa badumedi se nang le palo e hodimo ya batho ba sa tsebeng ho bala le ngola. Diphuputsong tse entsweng pejana diphuthehong tse fapaneng Bloemfontein ho ile ha fumaneha hore ke diperesente tse Il tsa badumedi ba sa tsebeng ho bala le ngola. Mme palo ena e ka nna ya eba hodimo le ho feta ha dipatlisiso tsena di ka etswa dibakeng tsa mahae. Ho diperesente tse 89 tse seetseng, ho ntse ho na le badumedi ba bangata ba ntse ba thatafallwa ke ho utlwisisa tsae ngotsweng Beibeleng ka baka la puo le tlotlontswe e thata haholo jwang ha ba e ballwa. Hona ho bolela hore ho tshwanetse hore ho be le phetolelo enngwe e tlang ho phethahatsa ditlhoko tsa batho ba sa tsebeng ho bala le ho ngola. Empa bothata ke hore: Ho ka fetolelwa Beibele jwang hore ekgone ho phethahatsa ditlhoko tse? Ka ha ma-Afrika ke batho ba utlwisisang ditaba ha di phethwa, ho bohlokwa hore mokgwa wa ho phetha 0 kenyeletswe Lentsweng la Modimo ka phetololo ya Beibele le ka dithero hobane ho phetha ke bohare ba tumelo ya ma-Afrika. Ho n

Published
2012

14. Novel application of near-infrared spectroscopy in detecting iatrogenic vasospasm during interventional neuroradiological procedures

Author

Sashmita Kumari Padhy, Neeraja Ajayan, Ajay Prasad Hrishi, Keta Deepak Thakkar, and Manikandan Sethuraman

Subjects
carotid artery stenting, cerebral vasospasm, near-infrared spectroscopy, Medical technology, R855-855.5, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

One of the complications of carotid artery stenting (CAS) is iatrogenic vasospasm caused by mechanical irritation of the blood vessel lumen by a guidewire, catheter, stent retriever, or distal protection devices. Although often self-limiting, the mechanical vasospasm can cause reduction in the cerebral blood flow and result in catastrophic ischemia, especially when undetected and persistent. Real-time cerebral oximetry with near-infrared spectroscopy (NIRS) could detect episodes of cerebral hypoxemia due to vasospasm and facilitate intervention for prevention of hypoxic brain injury during neuro-intervention procedures such as CAS. We present a case scenario where NIRS detected iatrogenic vasospasm even before the conventional tests could identify the event during CAS.

Published
2019
Full Text
View/download PDF

15. GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers

Author

Reiman, Eric M., primary, Webster, Jennifer A., additional, Myers, Amanda J., additional, Hardy, John, additional, Dunckley, Travis, additional, Zismann, Victoria L., additional, Joshipura, Keta D., additional, Pearson, John V., additional, Hu-Lince, Diane, additional, Huentelman, Matthew J., additional, Craig, David W., additional, Coon, Keith D., additional, Liang, Winnie S., additional, Herbert, RiLee H., additional, Beach, Thomas, additional, Rohrer, Kristen C., additional, Zhao, Alice S., additional, Leung, Doris, additional, Bryden, Leslie, additional, Marlowe, Lauren, additional, Kaleem, Mona, additional, Mastroeni, Diego, additional, Grover, Andrew, additional, Heward, Christopher B., additional, Ravid, Rivka, additional, Rogers, Joseph, additional, Hutton, Michael L., additional, Melquist, Stacey, additional, Petersen, Ron C., additional, Alexander, Gene E., additional, Caselli, Richard J., additional, Kukull, Walter, additional, Papassotiropoulos, Andreas, additional, and Stephan, Dietrich A., additional

Published
2007
Full Text
View/download PDF

17. Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease.

Author

Ndrepepa G, Braun S, Tada T, King L, Cassese S, Fusaro M, Keta D, Kastrati A, and Schmidt R

Subjects
Aged, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Coronary Artery Disease pathology, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Risk Factors, Biomarkers blood, C-Reactive Protein, Coronary Artery Disease blood, Fibrinogen
Abstract

Background & Objectives: The comparative prognostic value of C-reactive protein (CRP) and fibrinogen for cardiovascular events has been inconclusively investigated. t0 his study was carried out to compare the prognostic value of CRP versus fibrinogen in patients with coronary artery disease (CAD)., Methods: The study included 13,100 patients with coronary angiography-confirmed CAD. Plasma CRP and fibrinogen levels were measured before angiography in all patients. The levels of CRP>3 mg/l and fibrinogen>350 mg/dl were considered as elevated. The primary outcome was 1-year all-cause mortality., Results: Patients were divided into four groups: patients with CRP≤3 mg/l and fibrinogen ≤350 mg/dl (n=4206); patients with CRP≤3 mg/l and fibrinogen >350 mg/dl (n=3132); patients with CRP>3 mg/l and fibrinogen ≤ 350 mg/dl (n=1273) and CRP >3 mg/l and patients with fibrinogen >350 mg/dl (n=4489). There were 634 deaths: 75 deaths in patients with CRP ≤3 mg/l and fibrinogen ≤350 mg/dl, 91 deaths in patients with CRP ≤3 mg/l and fibrinogen >350 mg/dl, 87 deaths in patients with CRP >3 mg/l and fibrinogen ≤350 mg/dl and 381 deaths in patients with CRP >3 mg/l and fibrinogen >350 mg/dl (Kaplan-Meier estimates of all-cause mortality, 1.8, 3.0, 7.0 and 8.7 %, log-rank test P<0.001). The multivariate analysis showed that CRP [adjusted hazard ratio (HR)=1.31, 95% confidence interval (CI) 1.18-1.45, for each standard deviation increase in the logarithmic scale] but not fibrinogen [adjusted HR=0.99 (0.90-1.09), for each standard deviation increase in the logarithmic scale] was an independent correlate of mortality., Interpretation & Conclusions: The findings indicated that in patients with CAD, CRP was a better predictor of mortality than fibrinogen and offered prognostic information beyond that provided by the conventional cardiovascular risk factors.

Published
2014

18. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease.

Author

Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, Tada T, Schömig A, and Kastrati A

Subjects
Aged, Biomarkers blood, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Humans, Middle Aged, Percutaneous Coronary Intervention, Prognosis, ROC Curve, Risk Factors, Sensitivity and Specificity, Survival Analysis, Coronary Artery Disease blood, Coronary Artery Disease mortality, Fibrinogen analysis
Abstract

Evidence on the usefulness of fibrinogen for the risk stratification of patients with coronary artery disease remains inconclusive. The aims of this study were to investigate the association of fibrinogen with cardiovascular events and to assess whether this biomarker provides additional prognostic information on top of that provided by traditional cardiovascular risk factors. This study included 13,195 patients with angiography-proved coronary artery disease and fibrinogen measurements available. Receiver-operating characteristic curve analysis showed that the best fibrinogen cutoff for mortality prediction was 402.0 mg/dl. On the basis of this cutoff, patients were divided into 2 groups: the group with fibrinogen >402.0 mg/dl (n = 5,198) and the group with fibrinogen ≤402.0 mg/dl (n = 7,997). The primary outcome was 1-year mortality. All-cause deaths occurred in 393 patients with fibrinogen >402.0 mg/dl and in 246 patients with fibrinogen ≤402.0 mg/dl (Kaplan-Meier estimates of mortality 7.7% and 3.1%, log-rank test p <0.001). The relation between fibrinogen and mortality followed a J-shaped pattern, with lowest mortality in patients with fibrinogen concentrations of 295 to 369 mg/dl. After adjustment for cardiovascular risk factors and relevant clinical variables, fibrinogen remained an independent correlate of all-cause mortality (adjusted hazard ratio 1.07, 95% confidence interval 1.04 to 1.10, p <0.001, for each 50 mg/dl increase in fibrinogen level), but it did not improve the discriminatory power of the model for mortality prediction (integrated discrimination improvement 0.002, p = 0.32). In conclusion, in patients with coronary artery disease, fibrinogen is an independent correlate of mortality, but it does not provide additional prognostic information on top of that provided by traditional cardiovascular risk factors., (Copyright © 2013 Elsevier Inc. All rights reserved.)

Published
2013
Full Text
View/download PDF

19. Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina.

Author

Ndrepepa G, Braun S, Schulz S, Fusaro M, Keta D, Pache J, Seyfarth M, Mehilli J, Schömig A, and Kastrati A

Subjects
Aged, Angina, Stable mortality, Angina, Stable physiopathology, Biomarkers metabolism, Female, Humans, Linear Models, Male, Middle Aged, Predictive Value of Tests, Prognosis, Risk Assessment, Risk Factors, Severity of Illness Index, Angina, Stable metabolism, Natriuretic Peptide, Brain metabolism, Peptide Fragments metabolism, Troponin metabolism
Abstract

Background: High-sensitivity cardiac troponin (hs-TnT) and N-terminal probrain natriuretic peptide (NT-proBNP) are powerful predictors of mortality in patients with stable coronary artery disease. Whether their combined use may further improve mortality prediction in these patients is unknown., Materials and Methods: The study included 869 patients with stable coronary artery disease who underwent percutaneous coronary intervention. Hs-TnT and NT-proBNP were measured before angiography. Using median values of hs-TnT (0·008 μg L(-1)) and NT-proBNP (250·0 ng L(-1)) as cut-off points, patients were divided into four groups: low hs-TnT/low NT-proBNP group (293 patients with hs-TnT and NT-proBNP < median); low hs-TnT/high NT-proBNP group (142 patients with hs-TnT < median and NT-proBNP ≥ median); high hs-TnT/low NT-proBNP group (142 patients with hs-TnT ≥ median and NT-proBNP < median) and high hs-TnT/high NT-proBNP group (292 patients with hs-TnT and NT-proBNP ≥ median). The primary end point was all-cause mortality., Results: The 4-year follow-up was complete in 90·7% of the patients. There were 76 deaths during the follow-up: seven in low hs-TnT/low NT-proBNP, 8 in low hs-TnT/high NT-proBNP, 10 in high hs-TnT/low NT-proBNP and 51 in high hs-TnT/high NT-proBNP groups (mortality estimates, 2·5%, 5·9%, 7·4% and 18·1%, respectively; odds ratio = 8·64, 95% confidence interval 3·85-19·4, P < 0·001 for high hs-TnT/high NT-proBNP vs. low hs-TnT/low NT-proBNP). Inclusion of hs-TnT and NT-proBNP in the multivariable model increased the discriminatory power of the model regarding mortality prediction compared with the model without biomarkers (absolute and relative integrated discrimination improvement 0·039 and 26·0%, P = 0·0015)., Conclusions: Combined use of hs-TnT and NT-proBNP improves long-term risk prediction of mortality in patients with stable coronary heart disease., (© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.)

Published
2011
Full Text
View/download PDF

20. Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction.

Author

Ndrepepa G, Alger P, Fusaro M, Kufner S, Seyfarth M, Keta D, Mehilli J, Schömig A, and Kastrati A

Subjects
Acute Disease, Adult, Aged, Biomarkers, Female, Humans, Male, Middle Aged, Myocardial Infarction pathology, Myocardial Infarction physiopathology, Myocardial Reperfusion, Necrosis, Pericardium physiopathology, Ventricular Function, Left, Angioplasty, Balloon, Coronary, Coronary Circulation, Myocardial Infarction therapy, Myocardium pathology
Abstract

Aims: To assess the impact of reperfusion after primary percutaneous coronary intervention (PCI) on myocardial salvage and outcome of patients with acute ST-segment elevation myocardial infarction (STEMI)., Methods and Results: This study included 1,406 patients with STEMI undergoing primary PCI. Blood flow restoration at epicardial and tissue levels was assessed by Thrombolysis in Myocardial Infarction (TIMI) and myocardial perfusion grade (MPG). Patients had paired scintigraphic examinations before, and 7-14 days after intervention. Based on TIMI and MPG grades, patients were divided into three groups: patients with optimal epicardial/optimal tissue perfusion (TIMI=3/MPG=3; n=801), patients with optimal epicardial/suboptimal tissue reperfusion (TIMI=3/MPG ≤ 2; n=412) and patients with suboptimal epicardial/suboptimal tissue reperfusion (TIMI ≤ 2/MPG ≤ 2; n=193). In these groups, the median infarct size (25th-75th quartiles) in the 7-14 days scintigraphy was: 7.0% (1.0%-19.0%), 12.6% (5.0%-27.6%) and 18.7% (10.4%-33.7%) of the left ventricle (p<0.001); frequency of aborted myocardial infarction was: 15.5%, 10.0% and 4.7%, (p<0.001); estimates of 5-year mortality were: 7.8%, 16.0% and 20.1% (adjusted hazard ratio=0.43, 95% confidence interval 0.21-0.89; p=0.02 for optimal epicardial/optimal tissue vs suboptimal epicardial/suboptimal tissue reperfusion)., Conclusions: In patients with STEMI undergoing primary PCI, restoration of blood flow at epicardial and tissue levels was associated with increased myocardial salvage and improved long-term survival.

Published
2011
Full Text
View/download PDF

21. Retrograde salvage approach to treat tibial artery perforation during attempted revascularization of a chronically occluded artery.

Author

Fusaro M, Keta D, and Byrne RA

Subjects
Aged, Arterial Occlusive Diseases diagnostic imaging, Chronic Disease, Hemorrhage diagnostic imaging, Hemorrhage etiology, Humans, Male, Radiography, Tibial Arteries diagnostic imaging, Treatment Outcome, Wounds, Penetrating etiology, Angioplasty, Balloon adverse effects, Arterial Occlusive Diseases therapy, Balloon Occlusion, Hemorrhage prevention & control, Tibial Arteries injuries, Wounds, Penetrating therapy
Abstract

Arterial perforation is a well-recognized complication of attempted percutaneous revascularization of a chronic totally occluded tibial artery and typically necessitates termination of the procedure. This report describes a step-by-step approach on how to perform a direct posterior tibial artery puncture and a sheathless wire introduction, to salvage a case of tibial artery perforation induced during attempted anterograde recanalization of an occluded tibial artery. After control of blood loss, retrograde wire passage and balloon inflation can facilitate relocation of the anterograde wire in the true lumen allowing uneventful completion of the procedure. © 2010 Wiley-Liss, Inc.

Published
2010
Full Text
View/download PDF

22. Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention.

Author

Ndrepepa G, Keta D, Schulz S, Mehilli J, Birkmeier A, Neumann FJ, Schömig A, and Kastrati A

Subjects
Aged, Aged, 80 and over, Angioplasty, Balloon, Coronary adverse effects, Biomarkers blood, Cardiovascular Diseases etiology, Cardiovascular Diseases mortality, Coronary Artery Disease mortality, Female, Fibrinolytic Agents adverse effects, Germany, Hemorrhage blood, Hemorrhage etiology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Odds Ratio, Proportional Hazards Models, Risk Assessment, Risk Factors, Therapeutics, Time Factors, Troponin blood, Angioplasty, Balloon, Coronary mortality, Coronary Artery Disease therapy, Hemorrhage mortality
Abstract

Bleeding complications in patients undergoing percutaneous coronary interventions (PCIs) are associated with increased risk of subsequent mortality. We undertook this study to characterize the subset of patients with bleeding complications who are at an increased risk of death within the first year after a PCI procedure. The study included 331 patients with bleeding complications among 9 954 patients who underwent PCI. The primary outcome analysis was 1-year mortality. Within the first year following PCI there were 39 deaths among 331 patients (11.8%), with bleeding complications and 240 deaths among 9 623 patients without bleeding complications (Kaplan-Meier estimates of 1-year mortality; 11.8% vs 2.5%, odds ratio 5.09, 95% confidence interval 3.76-6.90, P < 0.001). Time to death (median [25th-75th percentiles]) was 38.5 [7.2-125.9] days in patients with bleeding complications vs 137.1 [68.3-234.0] days in patients without bleeding complications (P < 0.001). Compared with survivors (n = 292), nonsurvivors (n = 39) had a significantly more adverse risk profile. The Cox proportional hazards model identified the elevated troponin level as the only independent correlate of 1-year mortality (hazard ratio = 2.35, 95% confidence interval 1.04-5.31, P = 0.039). In conclusion, patients with peri-PCI bleeding complications who die have a more adverse cardiovascular risk profile than patients with bleeding complications who survive the first year after PCI. Patients with bleeding complications and an elevated troponin level are at high risk of death within the first year following PCI. The majority of deaths in patients with peri-PCI bleeding occur within the first 3 months after PCI procedure.

Published
2010
Full Text
View/download PDF

23. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction.

Author

Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schömig A, and Kastrati A

Subjects
Aged, Angioplasty, Balloon, Coronary mortality, Cohort Studies, Confidence Intervals, Coronary Angiography, Electrocardiography, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction diagnosis, No-Reflow Phenomenon diagnostic imaging, Odds Ratio, Postoperative Care methods, Probability, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Severity of Illness Index, Statistics, Nonparametric, Survival Analysis, Time Factors, Tomography, Emission-Computed, Single-Photon, Treatment Outcome, Angioplasty, Balloon, Coronary methods, Cause of Death, Myocardial Infarction mortality, Myocardial Infarction therapy, No-Reflow Phenomenon mortality
Abstract

Objectives: The objective of this study was to investigate the impact of no-reflow phenomenon on 5-year mortality among patients with acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI). This impact was also assessed in relation to infarct size., Background: The impact of no-reflow on long-term mortality in patients with STEMI has been insufficiently studied., Methods: This study included 1,406 patients with STEMI treated by primary PCI. No-reflow was diagnosed using angiographic criteria. Infarct size was measured with single-photon emission computed tomography imaging 7 to 14 days after the acute event. The primary outcome was 5-year mortality., Results: The no-reflow phenomenon was diagnosed in 410 patients (29%). Infarct size was 15.0% (6.0% to 29.0%) of the left ventricle in the no-reflow group versus 8.0% (2.0% to 21.0%) of the left ventricle in the reflow group (p < 0.001). There were 132 deaths during follow-up. Of them, 59 deaths occurred among patients with no-reflow and 73 deaths occurred among patients with reflow (Kaplan-Meier estimates of 5-year mortality 18.2% and 9.5%, respectively; odds ratio: 2.02; 95% confidence interval: 1.44 to 2.82; p < 0.001). The Cox proportional hazards model adjusting for infarct size among other variables identified the no-reflow phenomenon as an independent correlate of 5-year mortality (hazard ratio: 1.66; 95% confidence interval: 1.17 to 2.36; p = 0.004)., Conclusions: In patients with STEMI treated by primary PCI, no-reflow phenomenon is a strong predictor of 5-year mortality. No-reflow phenomenon after PCI provides prognostic information that is independent of and beyond that provided by infarct size., (Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2010
Full Text
View/download PDF

24. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction.

Author

Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, Mehilli J, Schömig A, and Kastrati A

Subjects
Aged, C-Reactive Protein metabolism, Coronary Angiography, Electrocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction epidemiology, Myocardial Infarction physiopathology, No-Reflow Phenomenon epidemiology, Predictive Value of Tests, Prognosis, Risk Factors, Survival Analysis, Angioplasty, Balloon, Coronary, Myocardial Infarction diagnosis, Myocardial Infarction therapy, No-Reflow Phenomenon diagnosis
Abstract

Background: The investigation of no-reflow phenomenon after percutaneous coronary intervention (PCI) in patients with acute ST-segment-elevation myocardial infarction has therapeutic implications. We investigated the predictive factors, persistence in time, and impact of no reflow on myocardial salvage, ventricular function, and mortality., Methods and Results: The study included 1140 patients with ST-segment-elevation myocardial infarction undergoing primary PCI and paired scintigraphic examinations (before intervention and 7 to 14 days thereafter). After primary PCI, 108 patients had no reflow and 1032 patients had normal coronary flow. The median salvage index was 0.34 (interquartile range, 0.15, 0.49) in patients with no reflow versus 0.55 (interquartile range, 0.29, 0.81) in patients with normal flow (P<0.001). Left ventricular ejection fraction at 6 months after PCI was 47.7+/-13.1% in the no-reflow group versus 54.2+/-13.9% in the group with normal flow after PCI (P<0.001). In 80.3% of patients with no reflow, normalization of blood flow >6 months after PCI occurred and correlated with improvement in the left ventricular ejection fraction. Independent predictors of no reflow were residual flow in the infarct-related artery (P<0.001), initial perfusion defect (P=0.03), C-reactive protein (P<0.001), and previous myocardial infarction (P=0.013). Kaplan-Meier estimates of 1-year mortality were 16.7% (n=18) in patients with no reflow versus 5.5% (n=56) in patients with normal flow (hazard ratio, 3.35; 95% CI, 1.97 to 5.69; P<0.001)., Conclusions: No reflow after primary PCI was associated with reduced myocardial salvage, larger infarct size, worse left ventricular ejection fraction at 6 months, and increased risk of 1-year mortality. In 4 of 5 patients with no reflow after PCI, restoration of normal flow occurred 6 months after reperfusion.

Published
2010
Full Text
View/download PDF

25. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.

Author

Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, Laugwitz KL, Neumann FJ, Seyfarth M, Berger PB, Schömig A, and Kastrati A

Subjects
Aged, Cohort Studies, Coronary Artery Disease mortality, Female, Hirudins, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Postoperative Hemorrhage mortality, Recombinant Proteins therapeutic use, Risk Factors, Stents, Treatment Outcome, Angioplasty, Balloon, Coronary, Anticoagulants therapeutic use, Coronary Artery Disease therapy, Heparin therapeutic use, Peptide Fragments therapeutic use, Postoperative Hemorrhage etiology
Abstract

Compared to unfractionated heparin (UFH), bivalirudin decreases bleeding during percutaneous coronary interventions (PCIs). We sought to investigate the association between periprocedural bleeding and 1-year mortality as a function of antithrombotic therapy with bivalirudin or UFH. This analysis of the association between bleeding with bivalirudin or UFH and 1-year mortality included the 4,570 patients with negative biomarkers enrolled in the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 3) trial. Major or minor bleeding occurred in 555 patients (12.1%): 225 patients treated with bivalirudin (9.8%) and 330 patients treated with UFH (14.5%, p <0.001). There were 82 deaths (1.8%) within the first year after PCI: 29 deaths occurred in patients who had bled, and 53 deaths occurred in patients who had not bled (Kaplan-Meier estimates of 1-year mortality 5.2% and 1.3%, odds ratio 4.12, 95% confidence interval 2.59 to 6.54, p <0.001). One year after PCI, there were 15 deaths in patients who bled with bivalirudin versus 14 deaths in patients who bled with UFH (Kaplan-Meier estimates of 1-year mortality 6.7% vs 4.2%, odds ratio 1.61, 95% confidence interval 0.76 to 3.40, p = 0.20). Major bleeding occurred in 70 patients (3.0%) treated with bivalirudin and 104 patients treated with UFH (4.5%, p = 0.008). One-year mortality was 11.4% (n = 8) in patients with major bleeding with bivalirudin versus 4.8% (n = 5) in patients with major bleeding with UFH (p = 0.10). In conclusion, these data suggest that in patients with negative biomarkers undergoing PCI, bivalirudin decreases bleeding after PCI compared to UFH, without affecting 1-year mortality in those who had bled., (Copyright 2010 Elsevier Inc. All rights reserved.)

Published
2010
Full Text
View/download PDF

26. Whole genome association analysis shows that ACE is a risk factor for Alzheimer's disease and fails to replicate most candidates from Meta-analysis.

Author

Webster J, Reiman EM, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Rogers J, Heun R, Jessen F, Kölsch H, Heward CB, Ravid R, Hutton ML, Melquist S, Petersen RC, Caselli RJ, Papassotiropoulos A, Stephan DA, Hardy J, and Myers A

Abstract

For late onset Alzheimer's disease (LOAD), the only confirmed, genetic association is with the apolipoprotein E (APOE) locus on chromosome 19. Meta-analysis is often employed to sort the true associations from the false positives. LOAD research has the advantage of a continuously updated meta-analysis of candidate gene association studies in the web-based AlzGene database. The top 30 AlzGene loci on May 1(st), 2007 were investigated in our whole genome association data set consisting of 1411 LOAD cases and neuropathoiogicaiiy verified controls genotyped at 312,316 SNPs using the Affymetrix 500K Mapping Platform. Of the 30 "top AlzGenes", 32 SNPs in 24 genes had odds ratios (OR) whose 95% confidence intervals that did not include 1. Of these 32 SNPs, six were part of the Affymetrix 500K Mapping panel and another ten had proxies on the Affymetrix array that had >80% power to detect an association with α=0.001. Two of these 16 SNPs showed significant association with LOAD in our sample series. One was rs4420638 at the APOE locus (uncorrected p-value=4.58E-37) and the other was rs4293, located in the angiotensin converting enzyme (ACE) locus (uncorrected p-value=0.014). Since this result was nominally significant, but did not survive multiple testing correction for 16 independent tests, this association at rs4293 was verified in a geographically distinct German cohort (p-value=0.03). We present the results of our ACE replication aiongwith a discussion of the statistical limitations of multiple test corrections in whole genome studies.

Published
2010

27. Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention.

Author

Ndrepepa G, Keta D, Byrne RA, Schulz S, Mehilli J, Seyfarth M, Schömig A, and Kastrati A

Subjects
Acute Coronary Syndrome complications, Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome mortality, Aged, Coronary Angiography, Female, Germany epidemiology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Obesity mortality, Odds Ratio, Proportional Hazards Models, Registries, Risk Assessment, Risk Factors, Thinness mortality, Time Factors, Treatment Outcome, Acute Coronary Syndrome therapy, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary mortality, Body Mass Index, Obesity complications, Thinness complications
Abstract

Studies that have tested the relationship between body weight as assessed by body mass index (BMI) and clinical outcome after percutaneous coronary intervention (PCI) have given contradictory results. The aim of the study was to investigate the impact of BMI on clinical outcome and assess the impact of adjustment for other cardiovascular risk factors on the relationship between obesity and clinical outcome in patients with acute coronary syndromes (ACS) following PCI. This study included 9146 patients with ACS who underwent coronary angiography and PCI: 2610 patients with ST-segment elevation acute myocardial infarction, 2792 patients with non-ST-segment elevation acute myocardial infarction, and 3744 patients with unstable angina. The primary outcome of this analysis was 1-year mortality. Quartiles of BMI were: 12.8 to <24.3 (1st quartile), 24.3 to <26.4 (2nd quartile), 26.4 to <29.1 (3rd quartile), and >29.1 to 50.7 (4th quartile). Within the first year following PCI, there were 756 deaths: 228 deaths in the 1st BMI quartile, 209 deaths in the 2nd BMI quartile, 161 deaths in the 3rd BMI quartile and 158 deaths in the 4th BMI quartile (Kaplan-Meier estimates of mortality 10.3%, 9.1%, 7.2%, and 7.0%, respectively; odds ratio [OR] = 1.51, 95% confidence interval [CI] 1.22-1.86, P < 0.001 for 1st vs 4th BMI quartile). After adjustment in the Cox proportional hazards model, the association between BMI and 1-year mortality was attenuated to the level of statistical insignificance (hazards ratio [HR] = 1.25, 95% CI 0.94-1.64; P = 0.127 for 1st vs 4th BMI quartile). In conclusion, in patients with ACS undergoing PCI, obesity as assessed with BMI was not an independent correlate of 1-year mortality.

Published
2010
Full Text
View/download PDF

28. Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy.

Author

Ndrepepa G, Keta D, Schulz S, Byrne RA, Mehilli J, Pache J, Seyfarth M, Schömig A, and Kastrati A

Subjects
Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction mortality, Myocardial Infarction physiopathology, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Thrombolytic Therapy methods, Angioplasty, Balloon, Coronary methods, Myocardial Infarction therapy, Myocardial Reperfusion mortality
Abstract

Purpose: The prognostic impact of low-flow reperfusion after percutaneous coronary intervention (PCI) in patients with ST-segment elevation acute myocardial infarction (STEMI) is unknown. The aim of the study was to investigate the impact of low-flow reperfusion after PCI in patients with STEMI., Methods: This study included 1,761 patients with STEMI with a baseline thrombolysis in myocardial infarction (TIMI) flow grade 0 and no collateral circulation to the infarcted region before primary PCI. The primary outcome was 1-year mortality., Results: At the end of PCI procedure there were 115 patients with post-PCI TIMI flow grade 0; 57 patients with TIMI flow grade 1; 218 patients with TIMI flow grade 2; and 1,371 patients with TIMI flow grade 3. At 1 year there were 36 deaths in patients with TIMI grade 0; 28 deaths in patients with TIMI grade 1; 42 deaths in patients with TIMI grade 2; and 162 deaths in patients with TIMI grade 3 [estimates of mortality 32.6, 49.1, 19.6 and 12.1%, respectively; odds ratio (OR) = 1.76, 95% CI 1.08-2.86, P = 0.02, for TIMI flow grade 1 vs. TIMI flow grade 0]. The Cox proportional hazards model identified post-PCI TIMI flow grade as an independent predictor of 1-year mortality [hazard ratio (HR) = 1.99, 95% CI 1.17-3.28; P = 0.01 for TIMI flow grade 1 vs. TIMI flow grade 0]., Conclusions: Patients with STEMI with totally occluded infarct-related arteries and no collateral blood flow to the infarcted region show a greater mortality with post-PCI TIMI flow grade 1 than TIMI flow grade 0.

Published
2010
Full Text
View/download PDF

29. Serum potassium levels on admission and infarct size in patients with acute myocardial infarction.

Author

Roos M, Ndrepepa G, Baumann M, Pan CR, Heemann U, Lutz J, Keta D, Schulz S, Byrne RA, Mehilli J, Schömig A, and Kastrati A

Subjects
Female, Humans, Middle Aged, Multivariate Analysis, Myocardial Infarction diagnostic imaging, Myocardial Infarction therapy, Retrospective Studies, Tomography, Emission-Computed, Single-Photon, Myocardial Infarction blood, Myocardial Infarction pathology, Patient Admission, Potassium blood
Abstract

Background: Little data exist on the relationship between potassium level and infarct size after ST-segment elevation acute myocardial infarction (STEMI). We investigated the influence of potassium levels on infarct size measured with single photon emission computed tomography (SPECT) in patients with STEMI after mechanical reperfusion., Methods: The study included 598 patients. Potassium measurements at baseline and 2 SPECT examinations, at baseline and 7-14 days after intervention, were performed. Infarct size in the 7-14 days SPECT and salvage index were the primary outcome analyses., Results: Tertiles of baseline potassium were: <4.05 mEq/L (1st tertile), 4.05-4.37 mEq/L (2nd tertile) and >4.37 mEq/L (3rd tertile). In potassium 1st, 2nd and 3rd tertiles, the infarct size in the 7-14 days SPECT (median [25th-75th percentiles]) was 9.0% [2.0%-21.8%], 10.0% [3.5%-22.0%] and 12.0% [5.0%-25.5%] of left ventricle (p=0.026); salvage index was 0.50 [0.26-0.84], 0.56 [0.26-0.81] and 0.40 [0.23-0.75] (p=0.09). Patients with anterior infarction in upper potassium tertile had greater infarct size compared with patients in lower potassium tertile (p=0.049). After adjustment in multivariable analysis, potassium was an independent correlate of infarct size in the 7-14 days SPECT (p=0.05)., Conclusions: In patients with STEMI, higher baseline potassium levels are associated with a larger scintigraphic infarct size.

Published
2009
Full Text
View/download PDF

30. Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention.

Author

Ndrepepa G, Braun S, Iijima R, Keta D, Byrne RA, Schulz S, Mehilli J, Schömig A, and Kastrati A

Subjects
Acute Coronary Syndrome diagnostic imaging, Aged, Biomarkers blood, Combined Modality Therapy, Coronary Angiography, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Leukocyte Count, Male, Middle Aged, Prognosis, Prospective Studies, Survival Analysis, Treatment Outcome, Acute Coronary Syndrome blood, Acute Coronary Syndrome therapy, Angioplasty, Balloon, Coronary, C-Reactive Protein metabolism
Abstract

Although an association between elevated leucocyte count and mortality in patients with ACS (acute coronary syndromes) has been established, the independence of this association from coronary risk factors and C-reactive protein has been inadequately studied. In the present study, this prospective registry included 4329 patients with ACS treated with PCI (percutaneous coronary intervention): 1059 patients with STEMI [ST-segment elevation MI (myocardial infarction)], 1753 patients with NSTEMI (non-STEMI) and 1517 patients with unstable angina. Blood samples were obtained before angiography for leucocyte count and C-reactive protein measurements. The primary outcome of this analysis was 1-year mortality. At 1 year, 345 patients (8%) had died: 45 patients in the 1st tertile, 93 patients in the 2nd tertile and 207 patients in the 3rd tertile of leucocyte count [Kaplan-Meier estimates of mortality, 3.2%, 6.4% and 14.1% with an OR (odds ratio)=2.42, 95% CI (confidence interval)1.78-3.12; P<0.001 for tertile 3 compared with tertile 2 and an OR=1.99, 95% CI 1.77-2.25; P<0.001 for tertile 2 compared with tertile 1]. The Cox proportional hazards model adjusting for coronary risk factors, ACS presentation, extent of coronary artery disease, C-reactive protein and other covariates identified leucocyte count with a HR (hazard ratio)=1.05 (95% CI 1.02-1.07; P<0.001 for 1000 cells/mm(3) increase in the leucocyte count), but not C-reactive protein (HR=1.13, 95% CI 0.95-1.34; P=0.15 for a 1 tertile increase in the C-reactive protein concentration) as an independent correlate of 1-year mortality. We conclude that elevated leucocyte count, but not C-reactive protein, predicts 1-year mortality independent of cardiovascular risk factors across the entire spectrum of patients with ACS treated with PCI.

Published
2009
Full Text
View/download PDF

31. Patterns of presentation and outcomes of patients with acute coronary syndromes.

Author

Ndrepepa G, Mehilli J, Schulz S, Iijima R, Keta D, Byrne RA, Pache J, Seyfarth M, Schömig A, and Kastrati A

Subjects
Aged, Angina, Unstable diagnosis, Angina, Unstable mortality, Angina, Unstable therapy, Electrocardiography, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Myocardial Infarction diagnosis, Myocardial Infarction mortality, Myocardial Infarction therapy, Proportional Hazards Models, Registries, Shock, Cardiogenic diagnosis, Shock, Cardiogenic mortality, Shock, Cardiogenic therapy, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome mortality, Acute Coronary Syndrome therapy, Angioplasty, Balloon, Coronary mortality, Stents statistics & numerical data
Abstract

Objectives: We undertook this study to assess the relationship between presentation pattern and mortality in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention., Methods: This registry included 10,455 patients with ACS, of whom 2,853 patients had ST-segment elevation myocardial infarction(STEMI), 3,060 patients had non-ST-segment elevation myocardial infarction (NSTEMI) and 4,542 patients had unstable angina. The primary outcome was 1-year mortality., Results: At 1 year there were 976 deaths, 390 (13.7%) among STEMI patients, 366 (12.0%) among NSTEMI patients and 220 (4.8%) among patients with unstable angina (OR = 1.17, 95% CI 1.01-1.35 for STEMI vs. NSTEMI; OR = 3.00, 95% CI 2.56-3.51 for STEMI vs. unstable angina, and OR = 2.58, 95% CI 2.20-3.04 for NSTEMI vs. unstable angina). In the Cox proportional hazards model ACS form was an independent correlate of 1-year mortality (HR = 0.90, 95% CI 0.73-1.13 for STEMI vs. NSTEMI; HR = 1.56, 95% CI 1.13-2.14 for STEMI vs. unstable angina; HR = 1.72, 95% CI 1.30-2.29 for NSTEMI vs. unstable angina)., Conclusions: The presentation pattern affects 1-year mortality in patients with ACS, with unadjusted mortality being highest in patients with STEMI and lowest in patients with unstable angina., (Copyright (c) 2009 S. Karger AG, Basel.)

Published
2009
Full Text
View/download PDF

32. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes.

Author

Ndrepepa G, Mehilli J, Schulz S, Iijima R, Keta D, Byrne RA, Pache J, Seyfarth M, Schömig A, and Kastrati A

Subjects
Acute Coronary Syndrome mortality, Acute Coronary Syndrome therapy, Aged, Blood Flow Velocity, Confidence Intervals, Coronary Angiography, Female, Humans, Kaplan-Meier Estimate, Male, Myocardium pathology, Odds Ratio, Perfusion, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Prospective Studies, Registries, Risk Factors, Stroke Volume, Thrombolytic Therapy, Time Factors, Acute Coronary Syndrome physiopathology, Angioplasty, Balloon, Coronary, Pericardium pathology
Abstract

Objectives: The aim of the study was to assess the relationship between baseline and post-procedural Thrombolysis In Myocardial Infarction (TIMI) epicardial blood flow grade and mortality in patients with acute coronary syndromes (ACS) who were treated with early percutaneous coronary intervention (PCI)., Background: The impact of baseline and post-procedural TIMI flow grade on mortality in patients with ACS has been insufficiently studied., Methods: This prospective registry included 10,455 patients with ACS who underwent coronary angiography and PCI: 2,853 patients with ST-segment elevation acute myocardial infarction, 3,060 patients with non-ST-segment elevation acute myocardial infarction, and 4,542 patients with unstable angina. The primary outcome was 1-year mortality., Results: At 1 year, there were 976 deaths: 117 deaths among patients with TIMI flow grade 0 to 1, 105 deaths among patients with TIMI flow grade 2, and 754 deaths among patients with TIMI flow grade 3 (Kaplan-Meier estimates of mortality 28.3%, 18.4%, and 8.0%, respectively; odds ratio: 1.66, 95% confidence interval [CI]: 1.57 to 1.76, p < 0.001, for TIMI flow grade 0 to 1 vs. TIMI flow grade 2 and odds ratio: 2.51, 95% CI: 2.06 to 3.06, p < 0.001, for TIMI flow grade 2 vs. TIMI flow grade 3). By using the Cox proportional hazards survival model, we identified post-PCI TIMI flow grade (hazard ratio: 0.60, 95% CI: 0.52 to 0.70; p < 0.001, for 1 grade increase in TIMI flow grade) but not baseline TIMI grade (hazard ratio: 1.08, 95% CI: 0.96 to 1.22; p = 0.20, for 1 grade increase in TIMI flow grade) as an independent correlate of 1-year mortality., Conclusions: In patients with ACS treated with early PCI, post-procedural TIMI flow grade but not baseline TIMI flow grade is an independent correlate of 1-year mortality.

Published
2008
Full Text
View/download PDF

33. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers.

Author

Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A, and Stephan DA

Subjects
Brain metabolism, Brain pathology, Brain physiopathology, Brain Chemistry genetics, Cell Line, Tumor, DNA Mutational Analysis, Gene Expression Regulation genetics, Gene Frequency, Genetic Markers genetics, Genetic Testing, Haplotypes genetics, Humans, Mutation, Neurofibrillary Tangles genetics, Neurofibrillary Tangles metabolism, Neurofibrillary Tangles pathology, Phosphorylation, Risk Factors, tau Proteins metabolism, Adaptor Proteins, Signal Transducing genetics, Alzheimer Disease genetics, Alzheimer Disease metabolism, Apolipoprotein E4 genetics, Genetic Predisposition to Disease genetics, Polymorphism, Single Nucleotide genetics
Abstract

The apolipoprotein E (APOE) epsilon4 allele is the best established genetic risk factor for late-onset Alzheimer's disease (LOAD). We conducted genome-wide surveys of 502,627 single-nucleotide polymorphisms (SNPs) to characterize and confirm other LOAD susceptibility genes. In epsilon4 carriers from neuropathologically verified discovery, neuropathologically verified replication, and clinically characterized replication cohorts of 1411 cases and controls, LOAD was associated with six SNPs from the GRB-associated binding protein 2 (GAB2) gene and a common haplotype encompassing the entire GAB2 gene. SNP rs2373115 (p = 9 x 10(-11)) was associated with an odds ratio of 4.06 (confidence interval 2.81-14.69), which interacts with APOE epsilon4 to further modify risk. GAB2 was overexpressed in pathologically vulnerable neurons; the Gab2 protein was detected in neurons, tangle-bearing neurons, and dystrophic neuritis; and interference with GAB2 gene expression increased tau phosphorylation. Our findings suggest that GAB2 modifies LOAD risk in APOE epsilon4 carriers and influences Alzheimer's neuropathology.

Published
2007
Full Text
View/download PDF

34. Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques.

Author

Anselmi M, Garbin U, Agostoni P, Fusaro M, Pasini AF, Nava C, Keta D, Turri M, Zardini P, Vassanelli C, Lo Cascio V, and Cominacini L

Subjects
Aged, Angina, Unstable diagnostic imaging, Angina, Unstable etiology, Biomarkers blood, Coronary Artery Disease complications, Coronary Artery Disease diagnostic imaging, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Oxidation-Reduction, Prognosis, Severity of Illness Index, Angina, Unstable blood, Coronary Angiography, Coronary Artery Disease blood, Lipoproteins, LDL blood
Abstract

Objectives: To measure circulating levels of oxidized-low-density lipoproteins (ox-LDL) in patients with stable and unstable angina and controls, and to investigate their correlation with the extent of coronary artery disease (CAD) and the presence of complex plaques at coronary angiography., Methods and Results: Circulating ox-LDL were assessed, using ELISA, in patients with unstable angina (UA, n=26), stable angina (SA, n=29) and in controls (C, n=27). All patients underwent coronary angiography. The extent of CAD was evaluated using a quantitative score, while the presence of complex, vulnerable plaques was angiographically assessed. Ox-LDL were higher in UA patients than in SA patients and in C subjects, and in SA patients than in C subjects (C, 45.6+/-12.8 U/L; SA, 58.8+/-11.0 U/L; UA, 73.7+/-13.6 U/L; p<0.001). No correlation was found with the extent of atherosclerotic disease in the coronary tree. Patients with angiographic complex lesions showed significantly higher levels of ox-LDL (68.4+/-13.9 U/L versus 55.2+/-16.4 U/L, p<0.001). Multiple regression analysis showed that ox-LDL were independent predictors of the presence of complex plaques (p<0.023)., Conclusions: Ox-LDL levels are higher in unstable patients and correlate with the presence of angiographically documented complex plaques. Ox-LDL might be markers of destabilization of CAD.

Published
2006
Full Text
View/download PDF

35. Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-kappa B activation in patients with unstable angina.

Author

Cominacini L, Anselmi M, Garbin U, Fratta Pasini A, Stranieri C, Fusaro M, Nava C, Agostoni P, Keta D, Zardini P, Sawamura T, and Lo Cascio V

Subjects
Aged, Angina, Unstable metabolism, Case-Control Studies, Female, Humans, Lipoproteins, LDL blood, Male, Middle Aged, NF-kappa B blood, Receptors, Oxidized LDL blood, Angina, Unstable blood, Cholesterol, LDL blood, NF-kappa B biosynthesis
Abstract

Objectives: The purpose of this study was to investigate the effect of circulating levels of oxidized low-density lipoprotein (ox-LDL) on nuclear factor-kappa B (NF-kB) activation in peripheral blood mononuclear cells (PBMC) of patients with unstable angina (UA) or stable angina (SA) and control subjects., Background: Nuclear factor-kB might be involved in atherosclerosis, as is suggested by the presence of activated NF-kB in human atherosclerotic lesions., Methods: Levels of plasma ox-LDL and circulating NF-kB in PBMC (and in separated lymphocytes and monocytes) were measured in 27 control subjects and 29 SA and 27 UA patients. In in vitro studies, the effect of ox-LDL and of the sera derived from a subgroup of UA patients and control subjects on monocytic NF-kB activation was also evaluated., Results: The UA and SA patients had higher levels of circulating ox-LDL and NF-kB in PBMC than control subjects (p < 0.001). The increase in circulating NF-kB was mainly due to the activation of monocytes. In the in vitro studies, ox-LDL dose-dependently increased the activation of NF-kB in monocytes, but not in lymphocytes derived from healthy volunteers. This increase was related to the expression of lectin-like ox-LDL receptor-1 on monocytes. The incubation of monocytes with the sera derived from the UA patients induced a significant increase in NF-kB activation compared with the sera derived from the control subjects., Conclusions: The data suggest that the activation of NF-kB in monocytes of UA patients is, at least in part, induced by circulating molecules such as ox-LDL, which has been found to be particularly elevated in UA patients.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results